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Neurodegenerative diseases have been becoming increasingly threatening to human life and 
living quality, especially to elderly people. Ideally, such diseases can be diagnosed using simple 
diagnostic methods and treated at their early stages using efficient drug delivery methods. Toward 
these goals, some new MEMS/microfluidic devices have been developed for diagnosing and 
treating these neurodegenerative diseases including Alzheimer’s Disease and Glaucoma.  
 One focus of this thesis is the multiplexed monitoring of two promising biomarkers, beta-
amyloid (Aβ42) and total tau (T-tau), in both buffer and cerebrospinal fluid (CSF) for Alzheimer's 
disease (AD) using label-free optical nanosensors. It has been found that 7.8 pg/ml of Aβ42 in 
buffer and 15.6 pg/ml of T-au in buffer can be readily detected with very good specificity. Based 
on our measurements, the purchased CSF itself contains Aβ42, whose concentration is estimated 
to be about 400 pg/ml. Aβ42 and T-tau in the mixtures of Aβ42 and T-tau spiked in CSF have been 
detected successfully, indicating the feasibility of the optical nanosensors to detect these 
biomarkers in clinical samples. For these measurements, only a small amount (~1 µl) of the 
samples is required. This type of sensor is suitable for point-of-care application to diagnose the 
AD due to its low cost and ease-of-operation. 
    The other focus of this thesis is to develop a new power-free multifunctional soft contact lens 
device that can measure intraocular pressure (IOP), achieve extended drug delivery in situ, and 
detect glaucoma biomarkers, all within the same device. Experiments demonstrate that the contact 
lens sensor can detect Interleukin 12p70, one possible biomarker for glaucoma, in a concentration 
as low as 2 pg/ml in artificial tears. The sustained drug release of the contact lens device can last 
up to 30 days. In ex vivo tests using cadaver pig eyes, the sensor can detect the IOP in a range of 






CHAPTER 1. INTRODUCTION 
Worldwide, the elderly population is growing. Within the next 30 years, 30 percent or more of 
the population will be aged 60 or more, in Europe, Canada, Japan, China, Chile and many other 
regions all over the world, as shown in Fig. 1.1. In the US, the percentage of people age 65 or more 
is expected to reach 20 percent by 2030 [1]. Elderly people, whose contributions have made the 
world better, although living longer than before, are more likely to be affected by diseases, such 
as glaucoma, hypertension, Alzheimer’s Disease (AD), Parkinson’s disease (PD), Huntington’s 
disease (HD), cardiac disease and cancers. Of these, glaucoma, AD, PD, and HD could be 
classified as neurodegenerative diseases, due to degeneration loss of functions, and death of 
neurons with aging. Neurodegeneration is the progressive loss of structure or function of neurons, 
including death of neurons. These diseases are usually incurable, leading to progressive 
degeneration and/or death of neurons. However, diagnosis and treatment of these diseases in their 
early stages could be critical to improve life for the elderly.  
 








Alzheimer's disease, a chronic progressive neurodegenerative disease, is the most prevalent type 
of dementia. Its most common early symptom is short-term memory loss. As the disease progresses, 
symptoms including problems with language, disorientation (including the likelihood of getting 
lost), mood swings, loss of motivation, lack of managing self-care, and behavior issues may 
develop. According to the recent data, the number of cases of AD is increases annually. In 2015, 
an estimated 29.8 million people worldwide were afflicted with AD, and the number may be 
presumed to be approximately 100 million by 2050, as shown in Fig. 1.2a. Current diagnostic 
methods for AD are based on neuron imaging, as shown in Fig. 1.2b. They include MRI imaging, 
PET and SPECT [2], and are expensive and time consuming. The challenge for such methods is 
for increased sensitivity and specificity in the diagnosis of Alzheimer's disease. Other methods 
therefore are urgently needed for diagnosing AD, particularly in the early stages or before 
symptoms occur.  
        
 








Current Literatures on Symptoms and Pathology Related to AD 
The death of neurons is an irreversible progress and even worse, no method can stop the loss of 
neurons by medication or surgery once AD is diagnosed. The early symptoms may include short 
term memory loss, followed by other symptoms already described. Such symptoms may occur 
unpredictably and cause serious problems for both patients themselves and their families. In 
numerous cases elderly people have gone missing or accidentally hurt themselves, as a result of 
undiagnosed Alzheimer’s diseases. This makes early diagnosis of such diseases essential for 
managing patients before their symptoms become severe.  
The inequality of distribution of dementia in six racial and ethnic groups in the U.S. has been 
studied to obtain data to support the work authorized by the National Alzheimer’s Project Act 
(NAPA) for reducing racial/ethnic disparities [4]. Researchers from University of California, San 
Francisco (UCSF) studied dementia incidences from Jan 1, 2000 to Dec 31, 2013 and 25-year 
cumulative risk in a total of 274283 health care facility members, shown in Fig. 1.3. All cases are 
aged 64+, with population size varying for different races: 18778 African-American; 4543 
American Indian/Alaska Native; 21000 Latino; 440 Pacific Islander; 206490 in white and 23032 
Asian-Americans. The dementia incidence was highest among African-Americans at 26.6/1000 
(person-years) and  American Indian/Alaskan Natives  at 22.2/1000 (person-years); medium for 
Latinos, at 19.6/1000 (person-years) and Pacific Islanders, at 19.6/1000 (person-years), and whites, 
at 19.3/1000 (person-years); and lowest for Asian-Americans, at 15.2/1000 (person-years). Thus, 
dementia incidence was 65% higher for the African-American group (95% confidence) than for 
the Asian-American group. The cumulative totals reveal that in every race/ethnic group, there is a 
25 percent incidence of dementia eventually. Females were found to have a higher dementia 







Fig. 1.3. Dementia incidence by race/ethnicity and sex [4]. 
 
    Alzheimer’s disease has been extensively studied in recent years to understand the disease 
producing mechanisms and potential ways to treat or cure this disease. The AD mechanisms have 
been well established; the main features of the disease are disfunction of neurons, loss of 
connections between neurons in close proximity, and subsequent death of neurons, as shown in 
Fig. 1.4. In the early stages of AD, these phenomena occur in the hippocampus and the entorhinal 
cortex, causing short term memory loss and mild cognitive impairment. As the disease progresses, 
an increased number of neurons and other parts of the brain are affected. Memory loss and 
cognitive impairment become more severe, and normal living can be seriously impaired. Death of 
neurons can finally spread through the entire brain, causing significant shrinkage of brain tissues. 
Following is a depiction of a healthy brain and a severely damaged brain, in which Alzheimer’s 







Fig. 1.4. Sketch showing brain cross-sections of healthy control and AD patient [2]. 
 
Neuron death is attributed mainly to deposition of Ab42 protein fibril aggregates onto neurons, 
which can be observed during the progress of Alzheimer’s disease. Three forms of Ab42 protein 
exist in human cerebrospinal fluid: monomer, oligomer and fibrillar in composition. The monomer 
form of Ab42 is dissolved in the cerebrospinal fluid, circulating in the system. The oligomer Ab42 
is the bonding form or crosslinked form of monomer Ab42, which can also be dissolved in 
cerebrospinal fluid and can potentially be crosslinked, forming insoluble fibrillar Ab42. The 
insoluble fibrillar Ab42 deposited onto neurons, would disrupt connections between adjacent 
neurons. Once these connections are lost, neurons die, forming large areas of plaque in the brain. 
After formation of oligomers and fibrillar Ab42, the concentration of monomer Ab42 in 
cerebrospinal fluid would thus be decreased.  
A related phenomenon of AD is the significantly increased concentration of Ttau biomarker in 
cerebrospinal fluid and blood, as shown in Fig. 1.5. Ttau consists of proteins that could stabilize 
microtubules, existing mainly in neural cells of central nervous system. Ttau, like Ab42, is 
considered toxic to neurons under certain circumstances. The tau hypothesis proposes that 
excessive or abnormal phosphorylation of tau in cerebrospinal fluid may result in the 






[5]. The accumulation of hyperphosphorylated tau in neurons is believed to lead to neurofibrillary 
degeneration [6]. Such tangles are toxic to cells, leading to cell death and cognitive decline. Tau 
could also be toxic to neurons by accumulation inside the cells, through a process involving 
enzyme stimulated phosphorylation of tau [7].  
 
Fig. 1.5. Trending of related biomarkers and structural changes before AD symptoms onset [5]. 
 
Diagnostic Methods with Neuron Imaging MRI, PET, SPECT, Principles and Costs 
The most widely used diagnostic method for AD before development of neuron imaging 
methods was based on NINCDS-ARADA criteria, established by the National Institute of 
Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease 
and Related Disorders Association (ADRDA) in 1984 [8]. The following figure Fig. 1.6 shows 
criteria for clinical diagnosis of AD. The main goal is to identify dementia on the basis of these 
criteria and classify it as to the stage of Alzheimer’s disease: PROBABLE, POSSIBLE, DEFINITE. 
In each stage, different symptoms are described as present or absent to support the presumed stage 
of Alzheimer’s disease. The standard examination methods consist of the medical history; 
neurologic, psychiatric, and clinical examinations; neuropsychological tests; and laboratory tests. 






(HD, PD, manic-depressive disorder, brain tumors) may have symptoms similar to those of AD. 
To improve the specificity for diagnosis of AD, neuron imaging has been introduced into clinical 
practice as a means of further examination.   
 
Fig. 1.6. Criteria for clinical diagnosis of AD [8]. 
 
The current diagnostic method for AD consists of two parts: diagnosis of dementia, and 
specificity examination with neuron imaging. Neuron imaging includes magnetic resonance 






Magnetic Resonance Imaging (MRI): A typical MRI machine is shown in Fig. 1.7a. It can 
provide indirect but solid evidence to help doctors with the diagnosis of certain diseases. MRI is 
based on changes of proton spin state. Certain radio wave frequencies would be absorbed by 
protons under a uniform magnetic field stimulation, changing the spin state from one to a higher 
level. Certain radio frequencies would be emitted after proton spin transfer from the upper level 
state to the relaxation state. Such signals can be captured and processed by means of Fourier 
transforms to obtain an intensity profile across an entire tissue region with automated scanning, as 
shown in Fig. 1.7b. The final image can be reconstructed to obtain cross-sectional intensity, 
providing biological information useful in disease diagnosis. The detected signal frequency is 
related to applied magnetic field intensity, which polarizes proton spin. The density of protons in 
different areas of tissue cross-sections would lead to differences in the emitting signal intensity, 
generating contrast in the gray scale image. Knowing the proton distribution would significantly 
increase the ability to diagnose tissue and organ variations in the targeted sample. Following are 
sketches showing how static magnetic field and gradient magnetic field would affect the signal in 
the frequency domain. As shown, broadband signal frequency varies with magnetic field intensity, 
indicating information on different cross section positions.  
An MRI image comparison of a healthy person and one with Alzheimer’s disease is shown in 
Fig. 1.7c. The gray scale image shows a cross section of a human brain under the same MRI 
conditions. White/black color indicates density of protons in specific areas, with whiter areas 
meaning higher intensity and more protons. The black areas indicate many fewer protons 
compared with whiter areas, meaning less tissue. As shown, compared to the healthy control brain, 
much less tissue is seen in the Alzheimer’s disease brain, which shows significant tissue shrinkage, 







Fig. 1.7. (a) MRI machine; (b) principle of MRI; (c) MRI brain comparison of control and AD patient [9]. 
 
Positron Emission Tomography (PET): PET, imaging method for diagnosis of Alzheimer’s 
disease, as shown in Fig. 1.8a, is based on detection of gamma rays from positron emission. When 
a positron collides with an electron in a low energy state, gamma rays are emitted. This method is 
usually used to observe metabolic activities in human tissues, especially related to glucose 
oxidation, as shown in Fig. 1.8b. To monitor metabolic activities related to glucose uptake, two 
molecules are required: a positron emitting radioligand which emits pairs of gamma rays, 
typically fluorine-18; and a radioactive tracer, typically fludeoxyglucose (FDG), which binds with 
radioligand to trace glucose. Intensity of gamma rays would reflect FDG concentration in a specific 
region, and the FDG concentration would indicate extent of glucose uptake, and thus the extent of 
metabolic activity in that specific region. The FDG tracer is commonly used to aid in the diagnosis 
of diseases of metabolic activities; cancer may be reflected by higher FDG concentration, whereas 







Fig. 1.8. (a) PET machine; (b) PET brain images comparison of Normal, MCI and AD patient [10]. 
 
The metabolic activities PET, although effective, is an indirect method of diagnosing disease. 
Different diseases may result in similar changes of metabolic activities, which compromises the 
specificity of such methods in diagnosing certain diseases. As more studies confirm the direct 
relationship of certain biomarkers with Alzheimer’s disease in human brain tissue and 
cerebrospinal fluid, such as Ttau and Ab42, more advanced PET systems have been developed that 
directly reveal concentrations/distributions of such biomarkers in human brain tissue. Fig. 1.9 
shows the Ttau PET signal and Ab PET signal obtained with healthy human brains and the brains 
of Alzheimer’s disease patients. The Ttau PET image indicates a much higher density of Ttau in 






more Ab42 deposition in brain tissue of AD patients than in healthy human brains. As already 
illustrated stated, Ab deposition in brain tissue would lead to loss of connections between neurons 
in close proximity and thus massive death of neurons, resulting in further shrinkage of brain tissue. 
The Ttau also becomes toxic to neurons and leads to their death.      
                             
Fig. 1.9. Ab and Ttau PET images of control and AD patient [11]. 
 
    Single Photon Emission Computed Tomography (SPECT): SPECT is similar to PET in that 
a radioactive ligand and molecule tracers are both used for generating emission of gamma rays, as 
shown in Fig. 1.10a. Detection of emitted gamma rays is also used in SPECT for generating 
computed images of tissues. However, SPECT is significantly different from PET in how the 
gamma rays are physically generated and in the number of dimensions the generated image may 
have. For PET, gamma rays are generated when positrons emitted by biological tracers annihilate 
with electrons. Two gamma photons of exact opposite directions would be, usually millimeters 
away. The detection of two photons in PET occur at the same time, making the spatial resolution 
around 1 cm. For SPECT, the gamma rays are directly emitted by the radioactive tracers, without 






hence the name ‘single photon’. The disadvantage of SPECT compared with PET is its lower 
resolution. However, three advantages of SPECT are worth mentioning. A SPECT machine 
usually costs 400,000 to 600,000 in the US, while a PET machine may cost 2,000,000. Another 
advantage is that SPECT is much less expensive to operate than PET, mainly due to its use of an 
easily acquired radioactive tracer. The third advantage is its three-dimensional imaging capability, 
originating from its rotated scanning of targeted organs and 3D rebuilding image with powerful 
post processing. In Fig. 1.10a, SPECT machine is shown. Compared to PET and MRI machines, 
the SPECT machine has a rotation stage for acquiring images in different cross sections to build 
three-dimensional organ and tissue images. Fig. 1.10b shows SPECT images of Alzheimer’s 
disease patient brain and a patient suffering from depression. The AD brain shows shrunken tissues, 
which agrees with images obtained by MRI or PET.  
 
Fig. 1.10. (a) SPECT machine; (b) SPECT images of AD patient and Depression patient [12]. 
 
Neuron imaging methods are direct methods to aid in the diagnosis of diseases, but they are 
sophisticated and expensive. As mentioned, SPECT and PET machines may cost 400,000-600,000 
and 2 million dollars, respectively. An MRI machine may cost from $150,000 to millions of dollars, 
depending on how complicated the specific MRI machine is. For instance, a state-of-the-art 3 Tesla 
MRI machine would cost up to 3 million dollars. The extremely high cost of such machines and 






a brain SPECT, the cost could be 1400 to 2800 dollars. PET costs average 3900 dollars for the 
brain, to 6700 dollars for the full body. Without insurance coverage, this would be a huge burden 
for people and their families.  
Another disadvantage of neuron imaging is its inability to diagnose Alzheimer’s disease early. 
Neuron imaging is usually the final step in confirming the doctor’s diagnosis on the basis of the 
patients’ symptoms, apparent in the late stages of Alzheimer’s disease. For the wellbeing of 
patients, such diagnostic methods cannot provide enough preventive procedures to improve 
patients’ better lives, since in the late stages of AD, all symptoms have appeared and brain damage 
has already occurred. Patients’ normal lives have already largely disappeared and the patient may 
have to depend on external care, especially because there is no effective treatment to reverse the 
brain damage and mitigate the dementia symptoms. The early detection of AD therefore is 
particularly critical to help families to plan patients’ future lives and take precautions regarding 
potential symptom-induced consequences (such as getting lost, injuring self by manipulating fire 
or electricity-based cooking equipment). 
    In addition, a neuron imaging method does not provide excellent specificity for diagnosing 
Alzheimer’s disease, especially because other types of dementia (Pick’s disease, Huntington’s 
disease) may also cause death of neurons and brain tissue shrinkage. The Ttau and Ab PET is 
definitely an improvement over the glucose PET, but is a qualitative evaluation of Ttau or Ab 
distribution in brain. For instance, one limitation of Ab42 is that it reflects only the density of Ab 
neuritic plaques in brain tissues. Further interpretation of Ab PET may take many other factors 
into consideration in making a conclusion, such as the individual patient’s profile and Ab 
deposition caused by other forms of dementia.  






expensive, and performing such neuron imaging methods to further confirm diagnosis comes too 
late, since damage is already done and little or nothing can be done after diagnosis has been made. 
A real challenge is to increase the sensitivity and specificity of such methods in the diagnosis of 
Alzheimer's disease, since there are other diseases that also cause brain tissue damage. Other 
methods are therefore urgently needed to help in the diagnosis of AD, particularly at the early 
stage, before symptoms appear.  
Other Sensing Methods, including MEMS and Nanotechnology Sensors 
Besides neuron imaging methods, other methods have been studied in an attempt to develop 
efficient and cost-effective yet dependable ways to help in the diagnosis of Alzheimer’s disease, 
or mild cognitive impairment dementia. As research related to Alzheimer’s disease goes deeper, 
other methods have indeed emerged for potential diagnosis of this disease in its early/preclinical 
stages. First things first: what is the early/preclinical AD stage? 
In some papers [13-14], preclinical AD is defined as “The silent stage of AD-when the disease 
has begun in the brain, but symptoms are not yet clinically evident”. The ultimate goal of 
diagnosing preclinical AD is to be able to apply some intervention at the preclinical stage, which 
may postpone or even eliminate the upcoming cognitive impairment that would occur if the 
condition were unattended. The preclinical AD stage could then be divided into three stages, based 
on different biomarker behavior and neuron imaging. Stage 1 should be characterized as Ab42 
PET results positive, while no neuron damage can be detected with MRI or FDG imaging. Stage 
2 would be characterized as Ab42 PET results positive and MRI neuron damage confirmed, 
although no cognitive damage is observed. In Stage 3, all results would be positive and mild 







Fig. 1.11. Characteristics for AD stages [13-14].  
 
Detailed information and standards for categorizing examination results in different stages are 
shown in Fig. 1.12. Ab PET result, markers of neuronal injury and evidence of subtle cognitive 
changes are qualitative indicators of disease progression. In combination, they could indicate the 
preclinical stages of AD.  
 
Fig. 1.12. Detailed illustration of each stage of preclinical AD [13-14]. 
 
In one study [15], functional near-infrared spectroscopy (fNIRS) was used to monitor changes 






accomplishes neuron imaging by utilizing energy of two wavelengths, 600nm/1000nm. 
Oxygenated hemoglobin and deoxygenated hemoglobin were the targeted chemicals because of 
their strong association with neuron metabolic activity in the cerebral cortex. Compared with MRI 
and PET, it has significant advantages with regard to high temporal resolution, low cost, non-
invasive monitoring, good portability and low movement constraints. The measurements showed 
consistently significant reductions of HbO concentration in the targeted group, as shown in Fig. 
1.13b. The decreased HbO concentration also agrees with the progress of disease severity from 
MCI to Alzheimer’s Disease, indicating that fNIRS is a potential valuable tool for early detection 
of Alzheimer’s disease and for monitoring the development of the disease.  
 
Fig. 1.13. (a) Graphical illustration of detectors and emitters distribution using fNIRS technology; (b) 
experimental results with fNIRS technology [15]. 
 
A strong correlation of the Ttau and Ab42 biomarkers with AD has been revealed as more and 






biomarker found to be related to Alzheimer’s disease was Ab42. In AD patients, in the brain plaque 
region where tissue was damaged, the fibril form of Ab42 was heavily deposited in tissues. Further 
studies then showed that the fibril form Ab42 was toxic to neurons by disrupting connections 
between adjacent cells. Lack of connections means further death of neurons. Further research 
indicates that the monomer form of the Ab42 biomarker is normally dissolved in cerebrospinal 
fluid, circulating inside the brain and spinal fluid and changing to oligomer Ab42 and fibrillar 
Ab42 as the severity of AD increases. The fibrillar Ab42, no longer soluble in cerebrospinal fluid, 
is aggregated and deposited onto surfaces of the brain. This causes death of neurons in the surface 
and shrinkage of brain tissues as the disease becomes more severe. The pathologies related to Ab42 
and dementia symptoms have been confirmed with MRI or Ab42 PET, which have detected Ab42 
plaque areas in shrunken brain tissues.  
 
Fig. 1.14. Longitudinal study results of cross-sectional analyses of clinical, cognitive, structural, metabolic, 







In another study, optical coherence tomography angiography was utilized for preclinical 
diagnosis of Alzheimer’s disease [16], as shown in Fig. 1.15a. The goal was to investigate whether 
there is a correlation between retinal or microvascular anatomy abnormality and potential 
Alzheimer’s disease. If such a correlation exists, examination of retinal or microvascular anatomy 
offers an alternative method of early diagnosis of Alzheimer’s disease. The study included 32 
participants; 58 eyes from 30 participants (62-92 years old) were selected for further analysis. All 
participants were cognitively normal and had no prior ophthalmic disease, media opacity, diabetes, 
or high intraocular pressure. The participants were considered potential AD cases if the Ab42 
biomarker examination was positive, meaning that PET revealed excessive Ab42 deposition or 
lowered Ab42 concentration in the CSF. Among the participants 14 were, on the basis of Ab42 
biomarkers, positive for AD and considered as having been diagnosed with preclinical AD; 16 
were not biomarkers positive and were therefore considered a control group. The combined results 
with PET with OCT showed that the total foveal avascular zone area was significantly increased 
in the biomarker positive group compared with control group.  In addition, the inner foveal 
thickness was decreased in the biomarker-positive group compared with control group, as shown 
in Fig. 1.15b. Findings indicated that individuals diagnosed as having preclinical AD (although 
cognitively normal) may have abnormal alternations of the retinal microvascular structure. This 
observation could provide ways of early AD diagnosis by performing ocular OCT, instead of more 







Fig. 1.15. (a) OCT results of FAZ for biomarker-positive and biomarker-negative people; (b) FAZ 
relationship with CSF biomarker results [16]. 
 
In the examples just described, the cerebrospinal fluid biomarker Ab42 was usually identified 
as the monomer. The advantage of directly measuring the Ab42 oligomer is that the oligomer form 
is more relevant as a cause of fibrillar Ab42 deposition on human brain tissues. A potential obstacle 
to detect oligomer Ab42 is its extremely low concentration in cerebrospinal fluid, which 
necessitates use of a highly sensitive method to detect it. A protein misfolding cyclic amplification 
technology was devised in this study, to amplify the oligomer concentration in cerebrospinal fluid 
[17], as shown in Fig. 1.16a. Oligomer Ab42 concentrations as low as 0.3-8.4 fM were used as 
seed to induce massive monomer Ab42 aggregation in the incubator and thus allow the detection 
of the minute amount of oligomer Ab42 present. The polymerization process is critically 
influenced by temperature, pH, and peptide concentration, which means that precise control of 
these parameters is essential, as shown in Fig. 1.16b. The aggregation of Ab42 is quantified by the 
fluorescence emission intensity of the amyloid-binding dye Thioflavin T (ThT); thus the 






shown in Fig. 1.16c. One contradictory finding in this study was that the concentration of Ab42 
oligomer was higher in CSF from AD patients than in CSF from those in the healthy group, shown 
in Fig. 1.16d. The explanation of the authors was that since the Ab42 oligomer is a very small 
proportion (1%) of the total Ab42 biomarker in cerebrospinal fluid, it is possible that total Ab42 
concentration is decreased even as oligomer Ab42 is increased. Therefore, simultaneous 
measurement of different forms of Ab42 may be a more promising way to increase the specificity 
of diagnosis of Alzheimer’s disease.   
 
Fig. 1.16. (a) (b) Amyloid formation with time changing; (c) ThT fluorescence intensity change with 
reaction time; (d) ThT fluorescence intensity change with initial seeds concentration [17]. 
 
In addition to the Ab42 and Ttau biomarkers, other biomarkers are under study to detect any 
correlation they have with Alzheimer’s disease [18]. One such biomarker is neurofilament light 
chain (Nfl), a promising fluid biomarker that could indicate cerebral disease progressions. 
Concentrations of Nfl in both cerebrospinal fluid and serum were measured in the control group 
(non-carriers) and in potential AD patients (mutation carriers). A strong correlation is found of Nfl 






Nfl concentration could reflect cerebrospinal fluid Nfl concentration. Also, transformation of the 
presymptomatic stage to the symptomatic stage (as early as 5 years before symptoms appear) leads 
to a peak rate change of the Nfl level in both serum and cerebrospinal fluid, which is confirmed 
by MRI at the same time, as shown in Fig. 1.17a-d. Such findings suggest that monitoring Nfl level 
makes it possible to predict AD symptoms and accomplish early diagnosis of AD. Another major 
contribution of this study is that it is a longitudinal study of participants over decades, providing 
progressive data and analysis for each stage of AD in the same patient. This is of real significance 
to providing early diagnosis and prediction of AD. The concentration in serum and cerebrospinal 
fluid is measured by single molecular array immunoassay technology (SIMOA, similar to the 
commercialized ELISA kit), which is based on bonding of antibody to antigen. The bonding is 
detected by light reading or fluorescence imaging equipment; Nfl concentrations in solutions are 
deduced on the basis of absorbed or emitted light intensities at certain wavelengths.  
 
Fig. 1.17. (a) (b) CSF and serum values of NfL concentration in Non-carriers and Mutation carriers; (c) (d) 







Another direction for achieving preclinical diagnosis of AD is development of cost effective and 
point-of-care MEMS devices of high specificity relative to other types of dementia, from the 
engineering perspective. Such MEMS devices should be capable of detecting biomarker 
concentrations in a reasonable range with sufficient sensitivity, achieving high specificity of the 
targeted biomarker relative to others, requiring no highly skilled personnel and expensive 
measuring equipment, being fabricated at much lower cost, and achieving continuous monitoring.  
One example is silicon nanopillar based biosensors, which immobilize various antibodies onto 
nanopillar surfaces and quantify biomarker/antibody bonding by measuring fluorescence intensity, 
as shown in Fig. 1.18. With this sensor, the antibody with better specificity is filtered out [19].  
 
Fig. 1.18. Illustration of fluorescence intensity with different biomarker concentrations with silicon 
nanopillar sensing platform [19]. 
 
In another example, the biosensor is focused primarily on oligomer Ab (amyloid-b-derived 
diffusible ligands, ADDLs) detection, because this allows for a more definitive diagnosis than 
detection of monomer Ab [20]. The minute concentration of Ab oligomer makes it difficult for 






with use of a sandwich process with oligonucleotide-modified Au nanoparticles and magnetic 
microparticles, as shown in Fig. 1.19a-c. The keys to the increased sensitivity of this sensor are: 
(1) immobilization of both Au NPs and MMPs with the same antibody to the ADDL antigen; (2) 
release of hundreds of bar-code DNA strands as the target being detected. Using this approach, 
concentrations as low as 200 aM ADDL could be detected. The study shows that AD patients have 
higher a concentration of ADDL than the control group: above 0.5 fM in AD patients and below 
than 0.5 fM in healthy control subjects.  
 
Fig. 1.19. (a) Amplification method of ADDLs; (b) Normalized intensity with respected to ADDL 
concentrations; (c) ADDLs concentration comparison of AD patient and healthy control [16]. 
 
In another study, SERS method was adopted to measure Ab42 and Ttau dissolved in CSF. 
Results showed that much lower concentrations could be detected than with the ELISA kit (0.312 
ng/ml for Ab42, 0.15ng/ml for Ttau) [21]. The technology studied and utilized in this paper is 






Nanoplatform. The core-shell nanoparticle is very effective in enhancing Raman signal by 
generating electromagnetic field hot spot; graphene oxide can chemically enhance Raman signal 
by influencing aromatic molecule interaction and having a large surface area onto which it can 
attach. The nanoplatform is reported to show high sensitivity and to have a detection limit as low 
as 100 fg/ml for both Ab42 and Ttau, shown in Fig. 1.20. 
 
Fig. 1.20. Core-Shell structure characterization with SEM, Raman and Absorbance [21].  
 
An optical LSPR biosensor was introduced later to measure the ADDL concentration in human 
brain extract and cerebrospinal fluids from both healthy controls and AD patients [22], as shown 
in Fig. 1.21a-b. LSPR, short for localized surface plasma resonance, usually leads to extraordinary 
light absorption or reflection at specific wavelengths. Such extraordinary light absorption or 
reflection results in a light intensity peak or dip in the broadband spectrum, which is highly 








Fig. 1.21. (a) Sketch and experimental setup for LSPR; (b) Experimental results of ADDLs detection [18]. 
 
An interesting work on Ab42 aggregation shows that ApoE4 could induce Ab42 aggregation 
more rapidly and specifically than Ab40 could, under conditions that mimicked biological 
conditions [23]. This study first reported on a biomimetic platform for real-time Ab42 aggregation 







Fig. 1.22. (a) Sketch of AuNP detection principle; (b) Ab40/42 detection results with ApoE4 [19]. 
 
An Interdigitated electrode of Gold (IDE-Au) was fabricated, and Ab42 antibody was 
immobilized onto its surface [24], as shown in Fig. 1.23a. Electrochemical impedance 
spectroscopy (EIS) was performed to measure the impedance change during the bonding process 
of Ab42 antibody and Ab42. The sensor had high selectivity and sensitivity, able to detect 
concentration as low as 10 pM, with detection range from 10 pM to 100nM. A portable device was 
then developed by minimizing entire systems and integrated with control circuits to form a point-
of-care device that is promising in real-time monitoring applications, as shown in Fig. 1.23b-c. 
 
Fig. 1.23. (a) Principle of IDE-Au immunosensor; (b) developed whole system with IDE-Au based 






A very interesting study based on square wave voltammetry was proposed for detection of 
soluble oligomer in CSF [25], as shown in Fig. 1.24. The surface electron transfer from Ferrocene 
is significantly influenced by surface bonding of the targeted Ab42 soluble oligomer. In scanning 
of the square wave frequency, increased absorption at 5 Hz occurs because of electron transfer, 
when the soluble Ab42 oligomer binds onto the chemically functionalized surface. By measuring 
the signal intensity, the concentration of soluble Ab42 oligomer can be deduced.  
 
Fig. 1.24. Principle of how square wave voltammetry works for detection of Ab soluble oligomer [25]. 
 
A metal–semiconductor field-effect transistor (MESFET) based biosensor was fabricated [3], as 
shown in Fig. 1.25a-c. The chemical linker/antibody is immobilized onto the MESFET gate and a 
channel is fabricated with carbon nanotube. When the chemical linker/antibody binds with Ab42, 
the threshold voltage of the field effect transistor is changed, causing the conductance of channel 






about concentration. The antibody sensor has proved to be superior to the chemical linker sensor 
with regard to sensitivity. And as low as 1 pg/ml Ab42 could be readily detected with antibody-
based biosensor.  
 
Fig. 1.25. (a) Sketch of MESFET based sensor and fabrication process; (b) surface functionalization process; 
(c) results of Ab biomarker detection with MESFET sensor [3]. 
 
Despite all these efforts, a device that is cost-effective, has a low detection limit, has high 
specificity and is capable of simultaneous detection of multiple biomarkers (Ab42 and Ttau) and 









Current Literatures on Glaucoma: Age, Symptoms, Species and Medication 
Glaucoma is a group of eye diseases that result in damage to the optic nerve and vision loss due 
to high pressure in the eye, as shown in Fig. 1.26a-b. Recent research has shown that glaucoma is 
also a kind of neuron degenerative disease. The most common type is open-angle glaucoma; less 
common are closed-angle glaucoma (also as angle-closure glaucoma) and normal-tension 
glaucoma. Open-angle glaucoma develops slowly over time and there is no pain. An estimated 6 
to 67 million people have glaucoma globally. The disease, which affects about 2 million people in 
the U.S., occurs more commonly among older people. Glaucoma has been called the "silent thief 
of sight" because the loss of vision usually occurs slowly, over a long period of time.  
 
Fig. 1.26 (a) Development of glaucoma; (b) diagnosis of glaucoma using complicated equipment [26]. 
 
According to recent research, glaucoma can be categorized as a neuron degenerative disease. 
Glaucoma is characterized by degenerative death of retinal ganglion cells and consequent 
deformation or shrinkage of the optic nerve head [27-30]. The death of retinal ganglion cells is 
believed to be caused by increased intraocular pressure, which is caused by intraocular fluid 
blockage. Glaucoma can be divided of two kinds, open-angle glaucoma and closed-angle 






90 percent of glaucoma patients have open angle glaucoma and the other 10 percent is closed-
angle glaucoma. As shown in Fig. 1.27a. open angle glaucoma is due to increased resistance to 
aqueous humor drainage through the trabecular meshwork, which makes exit of ocular fluid from 
the anterior chamber more difficult. Closed-angle glaucoma is due to obstruction of the drainage 
pathway due to deformation of the iris and its attachment to cornea. Because intraocular fluid 
circulation is blocked, significantly elevated pressure develops in the anterior chamber. Such 
increased pressure causes stress on eye structures, especially the posterior chamber and lamina 
cribrosa (LC). The thickness of the LC layer is reduced and retinal ganglion (RG) cells die, which 
finally leads to vision loss, as shown in Fig. 1.27b. 
About 25-50 percent of glaucoma patients do not have elevated intraocular pressure [31-32]. 
Instead, such patients may have abnormally low cerebrospinal fluid pressure, leading to a large 
pressure difference across the lamina cribrosa and optic nerve layer. This would also cause the 
same optic nerve damage as elevated intraocular pressure would cause. Also, although a strong 
correlation is found between high intraocular pressure and glaucoma, that does not mean elevated 
intraocular pressure would necessarily lead to glaucoma.  
 







The consequence of glaucoma is gradual loss of visual field [31], due to retinal ganglion cell 
death, as shown in Fig. 1.28. Death of retinal ganglion cells decreases the information transmitted 
to the brain, leading to partial or complete vision loss as glaucoma advances. The following figures 
show a comparison of normal vision and damaged vision due to glaucoma. For glaucoma damaged 
vision, there is partial field loss in the surrounding region of vision field center, and unbalanced 
color perception in the center region of vision. 
 
Fig. 1.28. Vision comparison of (a) glaucoma induced vison field loss and (b) health control [31].  
 
Diagnostic Method of Scanning Laser Tomography 
Screening for glaucoma is usually performed as part of a standard eye examination by an 
optometrist. Testing for glaucoma should include measurements of the intraocular pressure 
via tonometry, anterior chamber angle examination, and examination of the optic nerve for any 
visible damage. A formal visual field test should be performed. The retinal nerve fiber layer can 
be assessed with imaging techniques such as optical coherence tomography, scanning laser 
polarimetry, and scanning laser ophthalmoscopy. 
Tonometry is currently the fastest and easiest way to measure intraocular pressure [34-35], as 






of the tonometer is directly opposed onto the cornea. Force applied from the tonometer, causes the 
cornea curvature to be deformed and become flattened. After the flattened portion reaches a certain 
size (3.06 mm2), the applied force/area reaches a balance with intraocular pressure. The reading 
from the equipment is the measured intraocular pressure.  
 
Fig. 1.29. Application of tonometer for measuring intraocular pressure [34-35]. 
 
Optical coherence tomography (OCT) is another imaging method useful in diagnosis of 
glaucoma [36-39]. It is a widely used biological imaging method of analyzing muscles, eyes and 
other soft tissues. The principle of OCT is based on low coherence interferometry, meaning that 
interferences can happen only when lights travel the same distances, as shown in Fig. 1.30a. The 
entire system works like this: as light beam from an optical source is delivered to the pellicle mirror, 
which splits the light ray into two different separate beams, the reference ray and sample ray. Rays 
from the reference mirror would interfere with rays from samples’ reflection, when their optical 






into a surface profile of the detected tissues. Combined with the scanning of the reference reflector, 
this system would have the capability to image soft tissues, with the high penetration depth of 
infrared light wavelength. The following figures below show the difference between results with 
a normal retina and a glaucoma patient’s retina. Because of death of retinal ganglion cells, the 
glaucoma retina has a significantly larger damaged optic nerve head compared to the healthy 
control, as shown in Fig. 1.30b. 
 
Fig. 1.30. (a) Principle of OCT; (b) OCT images of health control and glaucoma patients [36-39]. 
 
Scanning laser polarimetry is best known for effective measurement of the retina nerve fiber 
layer (RNFL) thickness [40-42]. This technology could be suitable for glaucoma diagnosis because 
of special structures of retinal ganglion cells axonal shape and their distribution. The microtubules 
of ganglion cells would have a birefringence effect because of different refractive indices for 
polarization in the x direction and the y direction, as shown in Fig. 1.31a-b. Different phase shifts 
after light passes through retinal ganglion cells leads to thickness information revealing of RNFL 
details, providing objective evidence for diagnosis of optic nerve fiber damage and thus glaucoma, 














Methods Involving Contact Lenses, Implantable Devices for Eye Pressure Measurement 
Only when substantial death of retinal ganglion cell death has occurred would vision be affected, 
and the patient begin to realize the existence of glaucoma. However, damage has already occurred 
and there is no method is available to reverse this process; once the optic nerve fiber is damaged, 
it is damaged forever. Therefore, early detection of glaucoma is definitely meaningful for slowing 
down the progress of glaucoma, minimizing potential consequences, and giving better lives.  
Current diagnostic methods such as tonometry or optical coherence tomography and scanning 
laser polarimetry are not suitable for early diagnosis of glaucoma, because of their expense (~3000 
dollars for tonometer) and the level of skill required to operate such equipment (OCT, SLP). Also, 
methods such as OCT and SLP can be effective only after damage to the optic nerve fiber has 
already occurred, making them more suitable to confirm glaucoma rather than to predict glaucoma.  
Research on early diagnosis of glaucoma is currently focused on measuring the intraocular 
pressure, because of the strong correlation between elevated intraocular pressure and glaucoma. 
Glaucoma patients typically have intraocular pressure above 21mmHg-22mmHg [43-44], while 
healthy controls do not. Implantable devices [45-47] and noninvasive devices [48-50] have both 
been proposed as treatments. 
Figure 1.32a shows an implantable IOP system designed for measuring intraocular pressure [51]. 
The key part of this system consists of a microfluidics channel and gas reservoir. When the system 
is implanted, intraocular pressure pushes intraocular fluid into the microfluidics channel. The gas 
in the gas reservoir and channel would therefore be compressed so that its pressure is higher than 
in the normal situation. Increased gas pressure inside the channel/reservoir would counter the 
pressure of the entered intraocular fluid, so that a static balance is obtained with the gas/interface 






determined by the level of intraocular fluid pressure, thus achieving a quantitative measurement 
of IOP. The experimentally determined position of the gas/liquid interface is linearly related to 
intraocular pressure, as shown in Fig. 1.32b. 
 
Fig. 1.32. (a) An implantable IOP measurement system; (b) results showing position versus pressure [51].  
 
Another example is a contact lens fabricated with an antenna imbedded between layers of the 
lenses [52], as shown in Fig. 1.33a-f. The contact lens contacts the cornea of the eye, and any 
pressure change inside the eye would deform the contact lens and antenna. Deformation of the 
antenna results in a change of resonance frequency change, which is thus utilized as a transducing 
signal to indicate an intraocular pressure change. The contact lens is flexible and has good 
reliability. Stretching experiments have shown that the fabricated contact lens can tolerate up to 
10,000 bending cycles. In addition to use in intraocular pressure measurement, the contact lens 
could be used for measuring tear glucose concentration in tears.  
However, since some glaucoma patients do not have elevated intraocular pressure, simply 
measuring intraocular pressure does not provide sufficient evidence to predict glaucoma and 
accomplish early diagnosis of the disease. Use of implantable devices requires surgery for 
implanting device and involves increased cost and patient discomfort. Recent research has found 
one particular biomarker for glaucoma, IL12p70. Glaucoma patients have considerably lower 
IL12p70 concentrations in their tears, compared to healthy controls [53]. Therefore, including 






confirm or rule out early glaucoma. With regard to treatment, reducing intraocular pressure is 
current the only proven way to treat glaucoma so as to slow down its progress. Of course, surgery 
to open up the channel for flow of intraocular liquid is an option, but it is still not a cure. The 
common method, delivery of certain drugs (such as Timolol) that is effective but inconvenient, 
decreases intraocular pressure by use of eyedrops each day. 
 
Fig. 1.33. (a) Contact lens sensor structure illustration; (b) fabricated contact lens sensor; (c) transmittance 
of contact lens; (d) resistance change with lens curvature; (e) resistance change with elongation; (f) 
resistance change with stretching cycles [52].  
 
Simpler ways of diagnosing glaucoma, involving less complicated procedures and at lower cost 
are desirable. To this end, we will report on another technology to monitor eye pressure and treat 
glaucoma.  
Dissertation Organization 
The dissertation is mainly to summarize my research work during my four-year PhD studies at 






Alzheimer’s Disease and Glaucoma background and detection challenge; (2) Rapid multiplexed 
detection of beta-amyloid and total-tau as biomarkers for Alzheimer's disease in cerebrospinal 
fluid [54]; (3) Nanopore thin film enabled optical platform for drug loading and release [55]; (4) 
A flexible nanopore thin film enabled device for pressure sensing and drug release [56]; (5) High-
resolution, flexible, and transparent nanopore thin film sensor enabled by cascaded Fabry–Perot 
effect [57]; and (6) A multifunctional contact lens [58]; (7) future work. 
The first chapter is introduction to background of neurodegenerative disease, which includes 
literature review regarding pathological description of Alzheimer’s Disease (AD), conventional 
and current diagnostic methods of Alzheimer’s Disease and related challenge, our new label-free 
optical devices targeting point-of-care and early diagnosis of AD. Introduction also includes 
background description of glaucoma, which is also a neurodegenerative disease happened to eyes 
as aging. The developing process of glaucoma is introduced, and symptoms are illustrated. 
Challenges about early detection of glaucoma are mentioned and a new type of multifunctional 
contact lens device is proposed to monitor/treat glaucoma.  
The second chapter of this dissertation is about our proposed microfluidic device for 
demonstrating the simultaneous detection of two biomarkers for AD using Anodic Aluminum 
Oxide (AAO) nanopore optical interference sensing mechanism. Several microfluidic passive 
valves are designed in the microfluidics device to control the chemicals flow. The antibodies 
specific to different biomarkers are immobilized onto AAO nanopore sensing surfaces by 
NHS/EDC assisted chemical bonding method. Concentrations of biomarkers can be estimated and 
quantified by the shifts of the optical signals in the broadband visible light spectrum reflected from 







The third and fourth chapter of this dissertation are about developing flexible device for drug 
loading and releasing, also for pressure sensing. The AAO thin film is transferred onto PDMS 
flexible thin film, resulting in a flexible AAO thin film device. The drug is loaded onto the flexible 
device using a layer by layer nanoassembly process and the drug release process from the device 
into DI water is monitored. Due to its flexibility and optical interference properties, this type of 
flexible device can also be used as angle sensor and pressure sensor.  
The fifth chapter of this dissertation is about developing thin flexible AAO/PDMS substrate 
with new fabrication process, compared to thick flexible AAO/PDMS substrate. The thinner 
AAO/PDMS substrate has significantly improved flexibility and sensitivity. New fabrication 
process involves spinning coating uncured PDMS onto AAO film, peeling off AAO/PDMS with 
great cares and techniques. Thinner AAO/PDMS is capable of stretching, bending, random 
reshaping due to the improved flexibility from much thinner PDMS substrate. Improved sensitivity 
is mainly due to denser optical interference fringes introduced by PDMS thin film. With smaller 
FWHM of denser fringes, resolution is enhanced, and sensitivity is improved.  
The sixth chapter of this dissertation is about developing multifunctional contact lens. Originally 
from the Chapter 4, thin AAO/PDMS substrate are fabricated and integrated with a contact lens. 
The integrated contact lens has three functions: angular sensor for monitoring cornea curvature 
change due to intraocular pressure (IOP), detection of one glaucoma biomarker IL12p70, and 
sustained drug delivery to treat glaucoma. The angular sensor is sensitive enough for a minute 
curvature change due to its increased sensitivity. Antibody will be immobilized onto contact lens 
surface with similar surface functionalization procedures in Section one for detecting glaucoma 
biomarker. Sustained drug release becomes possible because of the large surface areas and 






The seventh chapter is about future work to improve current developed devices and target point-
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CHAPTER 2. RAPID MULTIPLEXED DETECTION OF BETA-AMYLOID AND 
TOTAL-TAU AS BIOMARKERS FOR ALZHEIMER'S DISEASE IN 
CEREBROSPINAL FLUID 
Chao Song*, Pan Deng*, and Long Que. Nanomedicine: Nanotechnology, Biology and Medicine, vol. 14, 
no. 6, pp. 1845-1852, 2018.  
Abstract 
    This paper reports the multiplexed monitoring of two promising biomarkers, beta-amyloid 
(Aβ42) and total tau (T-tau), in both buffer and cerebrospinal fluid (CSF) for Alzheimer's disease 
(AD) using label-free optical nanosensors. It has been found that 7.8 pg/ml of Aβ42 in buffer and 
15.6 pg/ml of T-au in buffer can be readily detected with very good specificity. Based on our 
measurements, the purchased CSF itself contains Aβ42, whose concentration is estimated to be 
about 400 pg/ml. Aβ42 and T-tau in the mixtures of Aβ42 and T-tau spiked in CSF have been 
detected successfully, indicating the feasibility of the optical nanosensors to detect these 
biomarkers in clinical samples. For the measurements, only a small amount (~1 μl) of the samples 
is required. This type of sensor is suitable for point-of-care application to diagnose the AD due to 
its low cost and ease-of-operation.  
Introduction 
    Alzheimer's disease (AD), as a chronic progressive neurodegenerative disease, is the most 
prevalent type of dementia. According to the Alzheimer's Association, the number of AD patients 
will almost double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Even 
though the diagnostic means such as neuroimaging methods (magnetic resonant imaging, positron 






improvement for the past decades, it is still a challenge to increase the sensitivity and specificity 
of a diagnosis of Alzheimer's disease. Until now, beta-amyloid (Aβ42), total tau (T-tau) and 
phospho-tau (P-tau) inside serum or cerebrospinal fluid (CSF) (Fig. 2.1a) are still the best 
biological markers to diagnose Alzheimer's disease and differentiate it from other forms of 
dementia with a high reliability and validity [1, 2]. Clinically relevant concentration ranges of 
Aβ42 and T-tau are 382.2 ± 102.0 pg/ml and at least > 300 pg/ml, respectively [3, 4]. Available 
methods such as neuroimaging and enzyme-linked immunosorbent assay (ELISA) have been used 
to detect Aβ42, T-Tau and P-tau [5, 6]. However, because of the requirements of the sophisticated 
equipment, the highly experienced personnel for the complicated operation, and the challenge of 
low detection limit, these methods are typically expensive and time-consuming, and not yet 
extended to and unsuitable for point-of-care (POC) diagnostics. To this end, some microsensors 
and nanotechnologies have been developed in recent years to address these issues. Examples 
include fluorescence imaging and electrochemical impedance spectroscopy based sensors for the 
detection of Aβ42 [7-9]. However, the technologies, which can provide ease-of-use platforms with 
high sensitivity and specificity, and suitable for POC diagnostics, are still critically needed. Herein, 
label-free monitoring of beta-amyloid and T-tau in CSF using optical nanosensors is reported. 
    The label-free nanosensor (Fig. 2.1b-c) is adapted from the nanostructured Fabry-Perot 
interference (nanoFPI) sensor developed in our lab [10, 11]. In this type of sensor, a layer of 
nanopores, which is the anodic aluminum oxide (AAO) embedded in the Fabry-Perot cavity, serves 
as the sensing element. The reflected white light from the nanoFPI sensor forms interference 







Fig. 2.1. (a) Sketch showing cerebrospinal fluid (CSF) inside the brain. Monitoring the biomarkers such 
as Aβ42, T-tau inside CSF to diagnoses Alzheimer's disease; (b) Schematic of a chip, consisting of four 
nanopore sensors; with integrated microfluidic network; (b) Close-up of nanopore thin film sensor and 
its operational principle. 
 
Methods 
Chemicals and Materials 
Aβ42 antibody and biomarker: Mouse anti-Amyloid Beta Peptide 42(Aβ42) monoclonal 
antibody (detector mAb) (cat. # MO-M40093B, Clone # CA9 10C11), ELISA kits for human Aβ42 
(Cat. # EL10057) were obtained from Anogen-YES Biotech Laboratories Ltd. (Mississauga, 
Canada). Aβ42 standard is reconstituted by standard diluent provided in the ELISA kit. 1mM 
AEBSF in protease inhibitor cocktail (cat. # P8340-1ML, Thermo Fisher Scientific Inc., IL, USA) 
is added to appropriate standard diluent before use. Nano-pore purified water is used to reconstitute 
anti-Aβ42 mAb to a concentration of 10 μg/ml.  
T-tau antibody and biomarker: Anti-Human Tau monoclonal antibody (200μg/ml, cat.# 






from Thermo Fisher Scientific Inc.(IL, USA). Human T-tau is reconstituted by standard diluent 
buffer provided in the ELISA kit. Nano-pore purified water is used to dilute anti-T-tau mAb to the 
concentration of 10μg/ml.  
Cerebrospinal fluid: Cerebrospinal Fluid (Pooled Human Donors) (cat. # 991-19-P) was 
purchased from Lee Biosolutions, Inc. (Missouri, USA).  
Materials/chemicals for surface functionalization of sensor surface: 11-Mecaptoundecanoic 
acid (HSC10COOH, 99%), 8-Mercapto-1-Octanol (HSC8OH, 98%), N-(3-Dimethylaminopropyl)-
N'-ethylcarbodiimide hydrochloride (EDC), N-Hydroxysuccinimide (NHS), and ethanolamine 
(EA), Phosphoric acid (PPA) and PBS buffer were purchased from Sigma-Aldrich (Milwaukee, 
WI) and used without further purification.  Deionized (DI) water was obtained from a DI water 
purification system (Millipore, FRANCE).  
Sensor Chip and Its Transducing Signals 
    A sensor chip consisting of four sensors fabricated from anodic aluminum oxide (AAO) nanopore 
thin film on a glass substrate is shown in Fig. 2.1b. The fabrication process is adapted from our 
previous work [12]. Its operational principle is illustrated in Fig. 2.1c. The Aβ42 antibody or T-tau 
antibody are immobilized on the chemically functionalized sensing surface. When the biomarker is 
bound to the antibody, the reflected optical signal (interference fringes) from the sensor will shift, 
which is used as the transducing signals and monitored by a spectrometer. Among the four sensors, 
one is used as a reference for control experiments, and the others are used to detect Aβ42, T-tau and 
the mixture of Aβ42 and T-tau, respectively. All these experiments have been carried out three 








Fabrication of the Sensor Chip 
    The fabrication process involves the following steps. (1) Fabrication of AAO thin film patterns 
as the sensing elements on glass substrate [12]: Aluminium thin film is deposited onto glass slides 
with E-beam evaporation. The aluminium is then transformed into AAO by electrochemical 
reaction in 0.3M Oxalic Acid, at 5.8 Celsius degree, for 2 hours. Photoresist AZ5214 is then spin-
coated onto surface and patterned as protection layer. Device is then immersed into AAO etchant 
to etch the unprotected AAO away. AZ5214 is then washed away, leaving the patterns of AAO 
thin film exposed, followed by coating a layer of 10 nm Au.  (2) Fabrication of microfluidic layer 
[13]: SU8-2075 is spin-coated onto glass slides with a thickness of 80 µm and patterned using 
photolithography, resulting in a SU8 mold. Liquid PDMS with precursor to cure agent ratio of 9:1 
is then deposited onto SU8 mold and cured at 65 Celsius for 2 hours. The PDMS microfluidic layer 
is peeled off from the mold. (3) The sensor chip is finally completed by bonding the PDMS 
microfluidic layer with the fabricated AAO thin film patterns on glass substrate after oxygen 
plasma treatment. The fabricated chip is shown in Fig. 2.2a. The close-up showing the four sensors, 
their inputs, their outputs and the microfluidic channels, and the nanopore thin film sensing 
elements is given Fig. 2.2b-c. The optical setup for the experiments is illustrated in Fig. 2.2d. 
 
Fig. 2.2. (a) Photo of a fabricated chip with four sensors and microfluidic interface; (b) close-up showing 
the main inlet Inpout0, and sub-inlet Input1 and sub-outlet Output1 for Sensor1; (c) SEM image of the 






Sensor’s Surface Functionalization Procedure 
    The sensor surface coated with10 nm Au is functionalized with either Aβ42 or T-tau antibody 
through 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)/N-hydroxysulfosuccinimide 
(NHS) chemistry. As shown in Fig. 2.3, the Au-coated sensor surface is immersed in the 10 mM 
HSC10COOH/HSC8OH for overnight and then washed with ethanol and DI water. After the 
surface is dried, the surface is immersed in a solution of NHS and EDC (NHS 0.2M, EDC 0.05M) 
for 2 hours. The sensor surface is washed with DI water and then immersed in the 10 µM antibody 
solution overnight. This is followed by loading of 100 μL 1 M ethanolamine (EA) to block the 
non-occupied HSC10COOH/HSC8OH sites activated by the EDC/NHS. Finally, the sensor 
surface is rinsed with the PBS buffer to flush off non-specifically adsorbed proteins. At this stage, 
the sensor is ready for the measurement.  
 
Fig. 2.3. Surface functionalization steps for the sensor surface from (a) to (e). In step (f), the biomarker 
is applied to the sensor. 
 
    Thereafter, Aβ42 or/and T-tau (in the buffer or CSF) will be applied to the sensors. After final 
sequential washes, the measurements will be taken. Experiments for negative controls are carried 






Chip Operational Procedure for Surface Functionalization and the Biomarker Detection 
    As shown in Fig. 2.1b and Fig. 2.2a, the chip consists of four sensors with one main inlet Input0. 
Each sensor has one sub-inlet and one sub-outlet. Use Sensor1 in Fig. 2.2b as an example, it has 
one sub-inlet Input1 and one sub-outlet Output1. From step a to step c in Fig. 2.3, the chemicals 
are flowed into chip through the Input0 located in the center of chip to functionalize the surfaces 
of the four sensors simultaneously. For step d of coating antibody to the sensors in Fig. 2.3, the 
antibody is flowed to each sensor through its sub-inlet.  For instance, for Sensor1 on chip, the Aβ4 
or T-tau antibody is flowed through its sub-inlet Input1 to immobilize one specific antibody. 
Similarly, one specific antibody will be functionalized on the surfaces of Sensor2, Sensor3 and 
Sensor4, respectively. This step allows different antibodies to be coated on each sensor, resulting 
in four Aβ42-sensors and/or T-tau-sensors, thereby enabling the multiplexed detection of different 
biomarker on the same chip simultaneously. The widths of the channels in the microfluidic 
network are properly designed so that the chemicals can be readily flowed to all four sensors 
through the main inlet Input0, but the chemicals through the sub-inlets can only be flowed to one 
specific sensor. For instance, in Fig. 2.2b, the chemical through input1 can only be flowed to 
Sensor1.   
As a demonstration of the microfluidic network, for the first few steps of surface 
functionalization, green food dye solution (used to mimic those chemicals) is flowed through main 
inlet Input0 to four sensors on chip (Fig. 2.4a). For the antibody coating, orange food dye (used to 
mimic the antibody) is followed into Sensor1 through its sub-inlet Input1, as shown in Fig. 2.4b. 
Similar procedure is used to coat the antibody to other sensors. Finally, the sample-to-be-detected 
is flowed into the chip through the main inlet Input0, and thus the sample can be detected by the 








Fig. 2.4. Optical images showing how the microfluidic network works: (a) green food dye (mimic the 
chemicals) to be flowed through the main inlet Input0 to all four sensors; (b) orange food dye (mimic the 
antibody) to be flowed to Sensor1 through its sub-inlet. 
 
Instrumentation 
    The detection setup of the sensors in Fig. 2.2d is the same as those previously reported [14, 15]. 
A broadband light source from a tungsten halogen lamp is coupled to a specifically-designed 
optical fiber probe (Ocean Optics, Inc., Dunedin, FL, USA), which illuminates the sensor surface 
perpendicularly. The reflected signals (transducing signals) are collected by the same optical fiber 
probe, leading to an optical spectrometer (Ocean Optics, Inc.), which can detect the optical 
spectrum from 350 nm to 1050 nm. The spectrometer is connected to a laptop computer for data 
acquisition and processing. The biochemical samples are transported to the chip through the 
assembled plastic tubes (Upchurch Scientific, Inc.) by a syringe controlled by a pump (Harvard 







Experimental Data Acquisition  
    The average shift of the fringes for the measured transducing signals is obtained by (i) firstly 
obtaining the shift of each fringe peak relative to that of the blank Au-coated AAO surface or the 
shift after the antibody has been immobilized on the AAO surface, and (ii) averaging the shift of 
all the peaks to obtain the error bars for the measurements. The reference for each average shift is 
specified in the context in the following sections. The transducing signal of the same sample is 
measured at least on three sensors to obtain the average value. 
Results 
Detection of Aβ42 in Buffer (Aβ42-buffer) and T-tau in Buffer (T-tau-buffer) 
    Aβ42 of different concentrations in buffer have been detected. The Aβ42 is diluted in buffer 
provided by the ELISA Kit, resulting in a series of concentrations of 500 pg/ml, 250 pg/ml, 125 
pg/ml, 62.5 pg/ml, 31.2 pg/ml, 15.6 pg/ml, 7.8 pg/ml, 3.9 pg/ml, respectively. The measured 
optical signals (fringe shift) are plotted in Fig. 2.5a. As shown, the fringe shift increases with the 
increasing concentrations of Aβ42. The shift is 6.5 nm when the concentration of Aβ42 reaches 
500 pg/ml. As low as 7.8 pg/ml of Aβ42 can be readily detected, which is better than those of 
previously reported biosensors [7-9]. Similarly, the T-tau is diluted in buffer with a series of 
concentrations of 2000 pg/ml, 1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.25 
pg/ml, 15.6 pg/ml, respectively. The measured results are shown in Fig. 2.5b. It shows when the 
concentration of T-tau is 2000 pg/ml, the shift is 3.76 nm. The lowest concentration of T-tau can 
be detected is 15.6 pg/ml. 
It should be noted that since the clinically relevant concentration range of Aβ42 for AD patients 






pg/ml to 500 pg/ml is sufficient enough to cover this range.  The clinically relevant concentration 
of T-Tau for AD patients is Age-dependent [2].  The following concentrations for normal T-tau 
levels have already been established [2]:  <300 pg/ml for ages between 21 and 50 years old; <450 
pg/ml for ages between 51 to 70 years old; and <500 pg/ml for ages between 70 and 93 years old.  
The measurement range of the sensor from 15.6 pg/ml to 2000 pg/ml can easily monitor the T-tau 
levels for AD patients. Hence, it is not critically important to further improve the detection limit 
of the sensor for both Aβ42 and T-tau.  
 
Fig. 2.5. (a) Measured transducing signals for an Aβ42-sensor to detect Aβ2 in buffer at different 
concentrations; (b) Measured transducing signals for an Aβ42-sensor to detect T-tau in buffer at different 
concentrations; (c) Measured transducing signals for a T-tau-sensor to detect T-tau in buffer  at different 
concentrations; (d) Measured transducing signals for a T-tau-sensor to detect Aβ2 in buffer  at different 
concentrations. 
 
Specificity Evaluation: Aβ42-buffer and T-tau-buffer 
    The specificity of the Aβ42 antibody functionalized sensors (Aβ42-sensor) has been evaluated 
by detecting T-tau-buffer. The measured optical signal for T-tau-buffer samples with different 
concentrations are given in Fig. 2.5c. The shift increases from 0.1 nm to 1.3 nm with the increased 






detecting Aβ42 in Fig. 2.5a, when the concentrations of Aβ42 increase from 0 pg/ml to 500 pg/ml, 
the shift increases from 1 nm to 6.5 nm, indicating very good specificity of the Aβ42-sensors. 
Similarly, the specificity of the T-tau antibody functionalized sensors (T-tau-sensor) has been 
examined by detecting Aβ42-buffer. The measured optical signal for Aβ42-buffer samples with 
different concentrations are given in Fig. 2.5d. The shift increases from 0.2 nm to 0.6 nm with the 
increased concentrations of Aβ42 from 0 pg/ml to 500 pg/ml. Compared to the measured optical 
signals for detecting T-tau in Fig. 2.5b, when the concentrations of T-Tau increase from 0 pg/ml 
to 500 pg/ml, the shift increases from 0.7 nm to 3.76 nm, indicating very good specificity of the 
T-tau-sensor.  These measurements suggest that the assay is suitable for detecting Aβ42 and T-tau 
in a complex biofluid such as in CSF. 
Detection of Aβ42 in CSF (Aβ42-CSF) and T-tau in CSF (T-tau-CSF) 
    Detection of the Aβ42 of different concentrations spiked in CSF has been carried out. Aβ42-
CSF samples are prepared as the following procedure. The CSF is obtained from Pooled Human 
Donors, the CSF itself contains Aβ42, but its concentration is unknown. The diluted Aβ42 samples 
have the following known concentrations: 500 pg/ml, 250 pg/ml, 125 pg/ml, and 62.5 pg/ml. Then 
the same volume of the diluted Aβ42 is spiked to the same volume of CSF. As a result, four Aβ42-
CSF samples (Sample1, Sample2, Sample3, and Sample4) are prepared but their exact 
concentrations of Aβ42 in these four samples have been changed and become unknown. Four 
Aβ42-buffer samples of the same known concentrations (500 pg/ml, 250 pg/ml, 125 pg/ml, and 
62.5 pg/ml) are also prepared for the experiments.  
The measured optical signals of Aβ42-CSF samples and Aβ42-buffer samples are given in Fig. 
2.6a. As shown, at the same Aβ42 concentration but below 500 pg/ml, the shift of the optical 






exits in CSF before additional Aβ42 is spiked to CSF. When the concentration of the added Aβ42 
in CSF and in buffer increases to 500 pg/ml, the shift of the optical signal from Aβ42-CSF samples 
becomes smaller than that from Aβ42-buffer samples. The Aβ42 concentration at the intersection 
point between the measured optical signals from the Aβ42-CSF samples and the Aβ42-buffer 
samples is the original Aβ42 concentration in CSF, which is ~ 400 pg/ml (Fig. 2.6a).  
 
Fig. 2.6. (a) Measured transducing signals of Aβ42 spiked in buffer and CSF, respectively; (b) Measured 
transducing signals of Aβ42 in Aβ42-T-tau mixture using an Aβ42-sensor, measured transducing signals 
of T-tau in Aβ420T-tau-mixture using a T-tau-sensor, respectively. 
 
A series of mixed samples is prepared by spiking both the diluted Aβ42-buffer and the diluted 
T-tau-buffer into CSF. Again, the diluted Aβ42-buffer samples have the following known 
concentrations: 500 pg/ml, 250 pg/ml, 125 pg/ml, and 62.5 pg/ml. The diluted T-tau-buffer 






buffer sample and the same volume of the diluted T-tau-buffer sample are spiked to the same 
volume of CSF. Namely, the mixed volume ratio for them is: Aβ42-buffer: T-tau-buffer: CSF= 
1:1:1. As a result, four Aβ42-T-tau-CSF samples are prepared but their concentrations of Aβ42 
and T-tau in the samples become unknown. Note that the CSF contains both Aβ42 and T-tau, hence 
the real concentrations of Aβ42 and T-tau in the four samples should be different from the 
concentrations of Aβ42-buffer samples and T-tau-buffer samples before they are spiked into the 
CSF samples. Specifically, since the volumes of the diluted Aβ42-buffer samples, the diluted T-
tau-buffer samples and CSF are the same for preparing the mixed samples, the real concentrations 
of both Aβ42 and T-tau in the mixed samples have been further diluted.   
These four samples have been detected by the Aβ42-sensor and the T-tau-sensor on chip, 
respectively. The measured optical signals from both sensors are plotted together in Fig. 2.6b. As 
shown, the measured optical signals for T-tau in the mixture (Aβ42-T-tau-mixture) have small 
variations, consistent with the same concentrations of T-tau in these mixed samples, again 
indicating the very good specificity of the T-tau-sensors. Otherwise, if the Aβ42 in the mixed 
samples can be efficiently bound to T-tau antibody, the change of the optical signals should be 
significant. In contrast, the optical signals for the Aβ42 in the mixture (Aβ42-T-tau-mixture) 
increases with its increased concentrations in the mixed samples as expected. In addition, the 
optical signal shifts for Aβ42 are smaller than those in Fig. 2.5a and Fig. 2.6a, confirming the real 
concentrations of Aβ42 in the mixture have been diluted in the mixed samples. 
Multiplexed Detection of Samples Mixed with Aβ42 and T-tau in CSF  
    To further demonstrate the multiplexed detection of Aβ42 and T-tau in the mimicking clinical 
samples, a series of samples has been prepared by spiking Aβ42 and T-tau at the clinically relevant 






concentrations of Aβ42 of 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5pg/ml, 31.25 pg/ml, and the T-
tau-buffer samples with concentrations of T-tau of 2000 pg/ml, 1000 pg/ml, 500 pg/ml, 250 pg/ml, 
125 pg/ml, respectively.  Then the Aβ42-buffer sample, the T-tau-buffer sample, and CSF are 
mixed together with a volume ratio of 1:1:1. As a result, 25 mixed samples in CSF are prepared. 
These 25 samples have been detected by Aβ42-sensors and T-tau-sensors on chip, respectively. 
 
Fig. 2.7. (a) Measured transducing signals of Aβ42 in Aβ42-T-tau mixture using an Aβ42-sensor; (b) 
measured transducing signals of T-tau in Aβ420T-tau-mixture using a T-tau-sensor.  
 
The measured optical signals by Aβ42-sensors are plotted in Fig. 2.7a. As shown, for the 
samples spiked with the same concentration of Aβ42, the measured optical signals have small 
variations, indicating the very good specificity of the Aβ42-sensors. Otherwise, if the T-tau in the 
mixed samples can be efficiently bound to Aβ42 antibody, the change of the optical signals should 






measured optical signals clearly increase with the increased concentrations of Aβ42 in the mixed 
samples. In addition, the optical signal shifts are consistent with those in Fig. 2.6b but smaller than 
those in Fig. 2.5a and Fig. 2.6a, confirming the real concentrations of Aβ42 in the mixed samples 
have been diluted.  
The measured optical signals by T-tau-sensors are plotted in Fig. 2.7b. Similarly, for the 
samples spiked with the same concentration of T-tau, the measured optical signals have small 
variations, again indicating the very good specificity of the T-tau sensors. Otherwise, if the Aβ42 
in the mixed samples can be efficiently bound to T-tau antibody, the change of the optical signals 
should be significant. For the samples spiked with the same concentration of Aβ42, the optical 
signals clearly increase with the increased concentrations of T-tau in the mixed samples.  
 All these measurements of the mixed samples demonstrate that these sensors can detect Aβ42 
and T-tau in CSF successfully with very good specificity and repeatability, indicating the sensor 
can potentially detect them in the clinical samples.   
Discussion 
In this effort, as a technical demonstration, four nanosensors on a chip have been fabricated. It 
should be noted that tens of nanosensors can be readily batch-fabricated on a chip inexpensively 
to increase the capacity for multiplexed detection if needed. The detection of two promising 
biomarkers Aβ42 and T-tau in buffer and in CSF for AD using these label-free optical nanosensors 
has been carried out. The typical detection time is less than 20 minutes after a biomarker is applied 
on the nanosensor, much faster than neuroimaging methods such as magnetic resonant imaging 
(MRI). It has been found that as low as 7.8 pg/ml of Aβ42 in buffer and 15.6 pg/ml of T-tau in 






lower detection limit than those of previously reported sensors. The detection of Aβ42 spiked in 
CSF has been performed. The measured optical signals show consistent larger shift for Aβ42-CSF 
samples than that of Aβ42-buffer samples at lower concentrations of the spiked Aβ42, while the 
shift becomes smaller for Aβ42-CSF samples than that for Aβ42-buffer samples at higher 
concentrations of the spiked Aβ42, which indicates the CSF itself contains Aβ42 and its 
concentration is estimated at ~400 pg/ml. Finally, the detection of the CSF samples spiked with 
both Aβ42 and T-tau has been demonstrated, suggesting the feasibility to monitor these biomarkers 
in clinical samples using the nanosensors. Furthermore, given its low cost and ease-of-operation 
with high sensitivity and specificity, this type of nanosensor can serve as a powerful point-of-care 
(POC) diagnostic tool if combined with the neuroimaging tool such as MRI. For instance, the 
nanosensor can serve as a POC equipment for early detection of the protein biomarkers in an 
efficient and cost-effective manner. If the sensor detects the changes of concentrations of the 
proteins that serve as Alzheimer’s biomarkers, it is a good indication that further tests are required, 
making the MRI the next step in the patient’s diagnosis and treatment. By this way, significant 
costs and time can be saved for patients, achieving more precision diagnostics of AD in a rapid 
and inexpensive way. 
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CHAPTER 3. NANOPORE THIN FILM ENABLED OPTICAL PLATFORM FOR DRUG 
LOADING AND RELEASE 
Chao Song, Xiangchen Che, and Long Que. Optics Express, vol. 25, no. 16, pp. 19391-19397, 2017. 
Abstract 
In this paper, a drug loading and release device fabricated using nanopore thin film and layer-
by-layer (LbL) nanoassembly is reported. The nanopore thin film is a layer of anodic aluminum 
oxide (AAO), consisting of honeycomb-shape nanopores. Using the LbL nanoassembly process, 
the drug, using gentamicin sulfate (GS) as the model, can be loaded into the nanopores and the 
stacked layers on the nanopore thin film surface. The drug release from the device is achieved by 
immersing it into flowing DI water. Both the loading and release processes can be monitored 
optically. The effect of the nanopore size/volume on drug loading and release has also been 
evaluated. Further, the neuron cells have been cultured and can grow normally on the nanopore 
thin film, verifying its bio-compatibility. The successful fabrication of nanopore thin film device 
on silicon membrane render it as a potential implantable controlled drug release device.   
Introduction 
Ideally for many diseases, including various ocular diseases, some chronic diseases and 
coronary heart disease, the controlled dose of drugs can be delivered locally for a sustained 
treatment [1-2]. Toward this goal, a variety of nanostructured materials, devices and systems have 
been developed to fulfil this requirement [3-7]. Among them, the nanoporous structure such as the 
porous Si has been used as a controlled drug delivery device [2]. Another widely used technology 






achieved by coating the drugs with multiple layers of chemicals by a layer-by- layer (LbL) 
nanoassembly process [8-9]. LbL nanoassembly process is based on the electrostatic attraction 
between oppositely charged polyelectrolytes. It is a simple yet powerful way for fabricating 
micrometer diameter shells/capsules to encapsulate drugs. Usually the wall permeability of 
synthesized capsules can be readily modified either by the chemical structures of the wall 
compositions or by external stimuli [8-10], which include pH and light. Specifically, by changing 
the pH of the solution around the chemically encapsulated drugs or using the light illumination to 
the capsules of drug, the nanopores inside the capsules can be dynamically changed or the wall of 
the capsules can be broken partially, facilitating the controlled drug release. Anodic aluminium 
oxide (AAO) nanopore, another nanoporous structure, is also an ideal drug delivery system with 
the following properties [11]. First, its nanopore size and volume can be easily modified; second, 
various drug loading to the nanopore structure is easy to carry out with simple chemical 
modifications; and finally, AAO is biocompatible. In addition, a unique property of AAO nanopore 
thin film is its ability to optically report on the loading or the release of a molecule or a drug within 
or from the porous nanostructure due to the change of the effective refractive index of the 
nanostructures [12]. In this paper, drug loading and release enabled by the AAO nanopore thin 
film and layer-by-layer (LbL) nanoassembly is reported. In addition, the effect of the nanopore 
size/volume on the release time has also been studied. Finally, the biocompatibility of the device 
and the successful fabrication of AAO nanopore thin film on silicone membrane have been 
demonstrated, indicating this type of device can be used as an implantable drug delivery device 







Materials and Methods 
Sketch showing how to load the drug to and release drug from the AAO nanopore thin film- 
based device is illustrated in Fig. 3.1. Drug model gentamicin sulfate (GS) is stored in the 
nanopores and in the stacked between poly (acrylic acid) (PAA) and chitosan (CHI) layers. The 
chemicals PAA, GS, CHI, and phosphate-buffered saline (PBS) are all purchased from Sigma. 
Concentrations of PAA, GS, and CHI are prepared to be 2mg/ml, 5mg/ml, and 0.12mg/ml, diluted 
in PBS 6.5.  
The drug loading process is illustrated in Fig. 1(a). During this process, an LbL nanoassembly 
process [13] is carried out. PAA, GS, PAA and CHI are applied onto the Au-coated nanopore thin 
film device in sequence and repeatedly. Due to their opposite charges and attractive electrostatic 
force among them, layers of [PAA/GS/PAA/CHI] is formed. Briefly, after PAA is applied for 5 
minutes on the Au-coated nanopore thin film surface, a two- consecutive rinse step with PBS 6.5 
is followed. The rinse ensures the less firmly bonded chemical PAA to be removed from the 
surface, allowing the next chemical layer GS deposition. 
 
Fig. 3.1. (a) preparation of AAO nanopore-thin film drug release device using LbL nanoasembly process 
(not to scale); optical micrographs showing the surfaces of the nanopore thin film (b) before and (c) after 








    Similarly, two consecutive rinse is carried out after the GS layer is formed before next layer of 
chemical is deposited. Following the same procedure, ten layers of [PAA/GS/PAA/CHI] 
combination are deposited in the whole loading process, resulting in totally forty layers of 
chemicals deposited onto the nanopore thin film surface. Fig. 3.1b-c gives the optical micrographs 
of the surface of the nanopore thin film before and after the ten layers of [PAA/GS/PAA/CHI] 
combination have been deposited. Due to the nature of AAO nanopores [18], the deposition of 
each chemical layer on the nanopore surface can be monitored by measuring the reflectance signals 
from the sample. The drug release process is illustrated in Fig. 3.1d. The sample is immersed into 
flowing DI water, which is utilized as the release solution. The release procedure can also be 
optically monitored by measuring the reflectance signals from the sample.  
The optical setup for monitoring the drug loading and release is shown in Fig. 3.2. It consists 
of a white light source, an optical fiber spectrometer, an optical fiber illuminating and collecting 
probe and a laptop computer.  
 
Fig. 3.2. Illustration of the setup for optical monitoring of drug loading and release process for an AAO 
nanopore thin film device.  
When the drug along with PAA and CHI is loaded to the nanopores and/or deposited on the 
nanopore thin film surface layer-by-layer, the effective refractive index of the device is changed. 






optically monitored. Similarly, when the drug (GS) is released from the device, namely the layers 
of GS/PAA/CHI is dissolved, again resulting in the optical signals’ change of the device.  
Results and Discussion 
AAO nanopore thin film device for drug loading and release: During the drug loading process, 
[PAA/GS/PAA/CHI] layer is repeatedly deposited ten times on the nanopore thin film. The 
measured reflectance optical signals for each [PAA/GS/PAA/CHI] layer is shown in Fig. 3.3a. In 
Fig. 3.3a, one of the peaks of optical signal from bare AAO nanopore thin film at wavelength of 
609 nm is selected as the reference peak. In the first two layers of [PAA/GS/PAA/CHI] deposition, 
the peak shifts to 607.8 nm. Starting from the third layer of deposition, the peak has a redshift 
eventually to 612.3 nm after deposition of the tenth layer, respectively. Overall, the peak has a 
blueshift of 1.2 nm and then has a redshift of 4.5 nm, leading to a net 3.3 nm redshift.  
 
Fig. 3.3. (a) Measured optical signals after each [PAA/GS/PAA/CHI] deposition cycle: clear optical 
signal peak shift is observed; (b) the shift of wavelength peak, relative to 609 nm, for each cycle of 
deposition.  
Fig. 3.3b shows almost linear increase of wavelength (i.e., peak red-shift) from the third layer 
to tenth layer deposition. The relationship of refractive index, thickness and resonant wavelength 
of this device is [15]: 2(n3t+n2d-n1t-n0d) = ml (1), where n3 is the effective refractive index of 






refractive index of chemicals filled in nanopores, n0 is the effective refractive index of chemicals 
deposited above nanopores, t is the thickness of AAO structure and d is the chemicals thickness 
on surface of AAO. As seen from Fig. 3.3b, the resonant wavelength peak shifts from 607.8 nm to 
612.3 nm, suggesting that n2d increases linearly while other items remain unchanged in equation 
(1). This indicates that [PAA/GS/PAA/CHI] layer is deposited on the surface of AAO thin film 
uniformly and the thickness of chemical layers increases linearly, consistent with previous work 
of other researchers [2]. However, for the first two layers chemical deposition as shown in Fig. 
3.3b, it shows a linear decrease of wavelength (i.e., peak blueshift). In the process of first two 
layers, chemicals are not only deposited on the surface of AAO, they are also trapped into the 
nanopores of AAO. The nanopore would accommodate a certain amount of chemicals, chemicals 
deposited onto the surface is less than chemicals trapped into nanopore. This leads to a blueshift 
of the resonant wavelength. After first two layers deposition, nanopore is filled with chemicals and 
no more chemical can be trapped into nanopore. Therefore, chemicals can only be deposited on 
the surface of AAO due to the attraction force between positive and negative charges, which leads 
to a redshift.  
Drug release process is facilitated by flowing DI water through the devices. As shown in Fig. 
3.4a, for the first 2 minutes, the peak has a blueshift of 1nm. Because of change with solution from 
PBS 6.5 to DI water, chemical ionization changes. The bonding force due to charge attraction 
becomes weak and deposited chemicals on AAO nanopore surface are dissolved, leading to drug 
release, resulting in a wavelength blueshift. In the next 8 minutes, the peak has a very small 
blueshift, approximately 0.5 nm. Peak shift has been observed for next 120 minutes, 600 minutes, 
1440 minutes, and 2800 minutes. During this period of time, the peak has a redshift rather than a 






the DI water. The much longer release time for them indicates that it is difficult for the 
chemicals/drug inside the nanopores to be released into the DI water, in comparison with the 
chemicals/drug stored in the layers deposited on the AAO nanopore surface. The wavelength peak 
shift during the whole release process is summarized in Fig. 3.4b.  
 
Fig. 3.4. (a) Measured optical signals from the device after chemical/drug releasing through DI water at 0, 
2, 120, 600, 1440, 2800 minutes, resulting in clear peak shift; (b) and the corresponding shifts at different 
release time.  
 
Nanopore size/volume effect on drug loading and release: In order to evaluate the nanopore 
size/volume effect on the drug loading and release, AAO nanopore thin film devices with two 
different sizes (~10nm and ~50nm) have been fabricated. SEM images of the nanopore thin film 
devices are shown in Fig. 3.5a. The device with enlarged pore size is supposed to provide larger 
volume to accommodate more drugs, and thus achieve longer release time.  
As shown in Fig. 3.5c-d, the measured optical signals of these two devices show the similar 
trend in both drug loading process and release process. During the loading process, the optical 
peak has blueshift in the first two layers and then redshift in the next eight layers. On the other 
hand, during the release process, the optical peak has blueshift in the first two minutes and then 
redshift until the releasing procedure is completed. But, for the Device2 with larger nanopore size 
(~50 nm), its optical peak shifts during the loading process and release process of the Device2 are 






indicates that more chemicals can be stored in the device, and thus larger dose of drug can be 
delivered for the same period of time (Fig. 3.5d). Hence, both the amount and the duration of the 
drug delivery can be modified by using AAO nanopore thin film with different nanopore 
size/volume to accommodate different amount of drugs. In these experiments, the time used for 
monitoring the drug release from these devices is only from 0 to 2800 minutes. As can be seen in 
Fig. 3.5d, even after 2800-minute release, the shift of the optical signals for both Device1 and 
Device2 still do not tend to become saturated, indicating that some drugs in both devices still 
remain to be released for an extended period of time.  
Evaluation of biocompatibility of AAO nanopore thin film: In order to prove the 
biocompatibility of the devices based on AAO nanopore thin film as potential implantable devices, 
the neuron cells have been cultured on the AAO nanopore thin film. Briefly, immortalized rat 
mesencephalic cells (1RB3AN27, N27 for short) are grown in RPMI medium supplemented with 
10% fetal bovine serum, 1% L -glutamine, penicillin (100 U/ml), and streptomycin (100 U/ml), 
maintained at 37°C in a humidified atmosphere of 5% CO2. Before we seed cells from the flask 
to AAO nanopore thin film, trypsin is used to detach the cells from the bottom of flask. After 2 or 
3 minutes, we pipette normal medium with 10% fetal bovine serum to the flask. Then the cells are 
seeded to AAO nanopore thin film. An optical image of neuron cells (N27) cultured on AAO 
nanopore thin film is shown in Fig. 3.6. Clearly the cells can spread and grow normally, verifying 








Fig. 3.5. (a) SEM images for AAO devices with nanopore size of ~10 nm and ~50 nm, respectively; (b) 
measured shift of optical signals for the devices during the LbL loading process; (c) the measured peak 
shifts after chemical/drug releasing through DI water at different release time. 
 
Fig. 3.6. Optical image showing the neuron cells’ (N27 cells pointed by read arrows) growth on AAO thin 
film device. 
Transferring of AAO nanopore thin film to silicone membrane: Even though the fabricated 
AAO nanopore thin film on the glass substrate can be peeled off, but it is quite crispy and easy to 
become curly and thus damaged (Fig. 3.7a), in order to make implantable or wearable AAO 
nanopore thin film device, the nanopore thin film need to be transferred to biocompatible substrate 
from the glass substrate. To this end, a process has been developed to transfer the AAO nanopore 






as the following: After the AAO nanopore thin film fabricated on glass substrate, the liquid 
adhesive PDMS-silicone membrane is applied uniformly on the nanopore thin film. After curing 
PDMS-silicone, the nanopore thin film along with the PDMS-silicone membrane can be gently 
peeled off the glass substrate. To verify the nanopore thin film is not damaged, the reflected optical 
signal from the thin film on silicone has been measured. As shown in Fig. 3.7c, the optical 
interference fringes can be observed, similar to that of AAO nanopore thin film on glass substrate 
[22]. While for the PDMS-silicone membrane without AAO nanopore thin film, no inference 
fringes can be observed. Further, it has been found no damages are observed after the nanopore 
thin film on PDMS-silicone membrane has been cyclically bent.  
 
 
Fig. 3.7. (a) photos showing the nanopore thin films peeled off glass substrate are damaged and/or become 
curly; (b) photos showing nanopore thin film transferred on PDMS-silicone; (c) measured optical signals 
indicate the nanopore thin film perfectly transferred to PDMS-silicone membrane.  
Conclusions 
In this paper, a drug loading and release device based on AAO nanopore thin film and LbL 
nanoassembly is reported. Both drug loading and release processes can be monitored optically for 
this type of device. The nanopore size effect on the drug loading and release has been evaluated. 






to load the drugs to the AAO nanopore thin film devices with nanopore size from ~10 nm to ~50 
nm. The bio-compatibility of AAO nanopore thin film has been demonstrated by culturing neuron 
cells on its surface. Further, AAO nanopore thin film has been successfully transferred to PDMS-
silicone membrane, indicating the AAO nanopore thin film-based device can be used as an 
implantable device for drug delivery.  
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CHAPTER 4. A FLEXIBLE NANOPORE THIN FILM ENABLED DEVICE FOR 
PRESSURE SENSING AND DRUG RELEASE 
Chao Song, Pan Deng, Xiaoke Ding, and Long Que. IEEE Transactions on Nanotechnology, vol. 17, no. 5, 
pp. 962-967, 2018. 
Abstract 
    A new multifunctional flexible nanopore thin film device for both drug release and pressure 
sensing is reported. Different from previously reported drug release device based on the nanopore 
thin film fabricated on rigid substrates, this new flexible device offers two functions: it not only 
can serve as a drug delivery device, but also can be used as a pressure sensor as well. Specifically, 
the periodically distributed honeycomb- shape nanopores in the device are used to store the drugs, 
facilitating the extended drug release. In addition, the applied pressure on the device deforms the 
nanopore thin film, causing the change of the incident angle of the illuminating optical light on the 
device surface. As a result, the reflected optical interference fringes from the device shift, which 
is used as a pressure transducing signal. It has been found that the pressure sensitivity is ~0.01 
nm/mmHg, and the drug release can be easily extended to three weeks for this type of flexible 
nanopore thin film devices.  
Introduction 
    Usually on-chip devices and electronic circuits are fabricated exclusively on rigid substrates 
with little mechanical flexibility. However, for some specific applications such as wearable 
devices, devices fabricated on elastic substrates will be much suitable and favored. To this end, for 
recent decades, fabrication of devices on deformable polymer substrates has given birth to the 






flexible substrates, including waveguides, microdisk resonators, add–drop filters and photonic 
crystals [2]. This progress on the 3D monolithic photonic integration technique on plastic 
substrates paves a way for opening up a variety of new application venues such as high-bandwidth-
density optical interconnects, conformal wearable sensors and ultrasensitive strain gauges. 
Flexible fluorescence sensors have been developed and demonstrated recently [3]. This technology 
may play an important role in developing some wearable diagnostic tools for monitoring the 
diseases based on fluorescence detection. And piezoresistive strain sensors have also been 
fabricated on plastic substrates [4]. This type of flexible strain sensor can be potentially integrated 
with stretchable or curvilinear substrates to enable some demanding strain mapping for biomedical 
applications and could be potentially used for intraocular pressure (IOP) monitoring [5], which is 
critical for diagnosis of glaucoma and monitoring of glaucoma treatment [6]. Nowadays, the 
flexible device technology has been widely used to fabricate different types of devices or sensors 
and has already demonstrated its significant impact on wearable sensing and drug delivery system 
among others [7-8]. Herein, a new type of flexible nanopore device for both drug release and 
pressure sensing is reported.  
Materials, Methods and Device Description 
    The materials used for fabricating flexible nanopore thin film (FLEX-nanopore-TF) include 
Polydimethylsiloxane (PDMS) (ELLSWORTH, Inc.) and high purity Al (IAM, Inc.). The 
materials used for drug release include Drug model gentamicin sulfate (GS), poly(acrylic acid) 









Fig. 4.1. Sketch of proposed FLEX-nanopore-TF (a-c) as a drug delivery device: drugs are stored inside the 
nanopores and the stacked nanoscale [PAA/GS/PAA/CHI] layers. The drugs are released by flowing water 
across the device; (d-e) as a pressure sensor: the shift of the interference fringes of the reflected optical 
signal as the transducing signal for pressure sensing. 
 
    The sketch of the FLEX-nanopore-TF device is illustrated in Fig. 4.1. The FLEX-nanopore-TF 
contains a layer of periodically distributed honeycomb-shape nanopores, which is anodic 
aluminum oxide (AAO) fabricated from an aluminum thin film using a two-step anodization 
process [9-11] and is tightly bonded to a layer of PDMS. As a drug delivery device, the nanopores 
in the FLEX-nanopore-TF are used to store drugs for extended drug release (Fig. 4.1a-c). The 
drugs are loaded into the nanopores and/or stacked on the surface of the nanopore thin film by 









Fig. 4.2. (a-b) Setup and its close-up for optical monitoring of the pressure applied on a FLEX-nanopore-
TF device; (c-d) incident angle of the illuminating light changes with the bending of the FLEX-nanopore-
TF device under applied pressure; (e-f) modeling results: the optical interference fringes reflected from the 
FLEX-nanopore-TF device shift when the incident angles change. 
 
     Meanwhile, as a pressure sensor, the nanopore thin film is used to optically monitor the pressure 
applied on the device (Fig. 4.1d-e). The illuminating light is perpendicular to the flat surface of 
the FLEX-nanopore-TF device, and the transducing signal is the reflected optical signal from the 
surface (Fig. 4.2a-b). When a pressure is applied on the FLEX-nanopore-TF device, a curvature of 
the FLEX-nanopore-TF device is formed due to its bending. As a result, the incident angle q of 
the illuminating light changes (Fig. 4.2c-d). Because of the changes of the incident angle q under 
different pressures, the peaks of the interference fringes of the reflected optical signal shift due to 
changes of the optical path [12]. The shift of the interference optical signal is used as the pressure 
transducing signal. Detailed optical model of FLEX-nanopore-TF device showing pressure 






    One representative modeling result based on rigorous coupled-wave analysis (RCWA) using 
RSoftTM is shown in Fig. 2e-f [13]. In this model, the FLEX-nanopore-TF device is measured 18 
mm long, 13 mm wide and 1.5 mm thick. The nanopore size is 50 nm in diameter, and the 
interspacing among nanopore is 100 nm. As shown, when the FLEX-nanopore-TF device is 
deformed horizontally by applying axial pressure P, the incident angle of the illuminating light is 
changed from 0° to 5°, 10°, 15° and 20°, as a result, the shift of the optical signal is 1.2 nm, 3.2 
nm, 7.6 nm, 14.8 nm, respectively. 
 
Fig. 4.3. Process flow to fabricate nanopore thin film on flexible substrate: FLEX-nanopore-TF. 
 
Fig. 4.4. Photo of (a) a FLEX-nanopore-TF; (b) a bended FLEX-nanopore-TF; (c-d) SEM images showing 







Experimental Results and Discussion 
Fabrication of Flexible Nanopore Thin Film 
    The process flow for fabricating FLEX-nanopore-TF is illustrated in Fig. 4.3. Briefly, after a 
layer of Al with high purity is deposited on glass substrate, anodic aluminum oxide (AAO) 
nanopore thin film is fabricated from Al thin film on glass substrate using a two-step anodization 
process [11], then the AAO nanopore thin film is immersed in liquid PDMS, followed by 65 °C 
curing for 2 hrs. Thereafter, AAO nanopore thin film along with a layer of PDMS is peeled gently 
off the glass substrate, resulting in a FLEX-nanopore-TF. The photos of the fabricated FLEX-
nanopore-TF and a SEM image of the nanopores in the thin film are given in Fig. 4.4. Typical 
thickness of PDMS for this device is ~3 mm and the thickness of the nanopore thin film is ~3 µm. 
    The mechanical property and reliability of the FLEX-nanopore-TF has been evaluated. It has 
been found that no cracks are observed in the FLEX-nanopore-TF after cyclic bending (Fig. 4.4b), 
indicating its good flexibility. 
Pressure Sensing Using FLEX-nanopore-TF Device 
    Using the setup in Fig. 4.2a, the applied pressure on the FLEX-nanopore-TF device can be 
calculated by measuring the horizontal displacement of the two ends of the FLEX-nanopore-TF 
device, given the pressure is applied along its horizontal axis of the device (Fig. 4.5). Based on the 
bending curvature, the mechanical properties of PDMS (i.e., Young’s modulus of 600 kPa [14], 
etc.) and the displacement of the both ends of the FLEX-nanopore-TF device, the applied pressure 










Where p, F are the applied pressure and force on the two ends of the device, respectively.  L0 is 
the original length, A is the cross-section area of the FLEX-nanopore-TF. E is the Young’s 
modulus of PDMS. a is the angle and d is the length shown in Fig.5a, respectively. 
 
Fig. 4.5. Sketch showing (a) the bending of the FLEX-nanopore-TF before and after being applied with a 
compressive pressure; (b) close-up showing the bending of the FLEX-nanopore-TF. 
 
    As shown in Fig. 4.6a, the shift of the peak of the optical signal is clearly observed under 
different applied pressure on the device. Note that the optical responses of the FLEX-nanopore-
TF device are monitored by an optical fiber-based optical spectrometer as shown in Fig. 4.2a. It 
has been found the peak has a blue-shift with increased compressive pressure. And its sensitivity 
of the FLEX-nanopore-TF based pressure sensor is ~0.01 nm/mmHg. The simulated results match 














Fig. 4.6. (a) Measured optical signals from the device under different pressure; (b) measured shift of the 
peak of the reflected optical signal from the device and the simulated peak shift of the optical signal under 
different pressures. 
 
Drug Loading Process 
 
Fig. 4.7.  Sketch: the drug loading to the nanopore thin film using layer-by-layer (LbL) nanoassembly 
process (not-to-scale). 
 
    In the experiments, the concentrations of PAA, GS, and CHI are prepared to be 2 mg/ml, 5 
mg/ml, and 0.12 mg/ml, respectively, which are all diluted in PBS 6.5. First, the drug loading to 






the drug loading process in Fig. 4.7, [PAA/GS/PAA/CHI] layer is repeatedly deposited ten times 
on the nanopore thin film using layer-by-layer (LbL) nanoassembly process [17]. And the loading 
process can be monitored optically by measuring the reflected signal from the device surface, 
similar to the setup in Fig. 4.2a.  
 
Fig. 4.8. (a) Measured interference optical signals after deposition of each layer [PAA/GS/PAA/CHI]; (b) 
Measured shift of the optical signal after disposition of each layer during the loading procedure. 
 
    The measured reflectance optical signal for each deposited [PAA/GS/PAA/CHI] layer is shown 
in Fig. 4.8. One of the peaks of optical signal from bare AAO nanopore thin film at wavelength of 
647 nm is selected as the reference peak. After the first layer and second layer of 
[PAA/GS/PAA/CHI] deposition, the peak has blueshift to 643 nm. Starting from the third layer of 
deposition, the peak has a red shift, and eventually to ~684 nm after deposition of the tenth layer. 






nanopore thin film due to the deposition of the [PAA/GS/PAA/CHI] layers [18]. The shift of the 
interference fringes of the reflectance optical signal is caused by the changes of effective refractive 
index of nanopore thin film due to the coated layers, which is different from the reason of the 
changes of the incident angle of illuminating light for pressure sensing in Fig. 4.2 and Fig. 4.5. 
Drug Release Process 
    Drug release process is realized by flowing DI water through the devices in Fig. 4.9. The 
measured reflectance optical signals during the drug release procedure are shown in Fig. 10a. The 
shift of the peaks of the optical signals are clearly observed. As shown in Fig. 4.10b, for the first 
2 minutes, the peak has a blueshift of ~1nm. This is because the deposited chemicals on AAO 
nanopore surface are dissolved, leading to drug release. Then the peak has a redshift, suggesting 
the chemicals/drug stored inside the nanopores start to be released into water. Peak shift has then 
been observed for next 120 minutes, 600 minutes and 1440 minutes. During this period of time, 
the peak has a redshift, suggesting the chemicals/drug stored inside the nanopores start to be 
released into the DI water [18]. The wavelength peak shift during the release process from 0 min 
to 1440 min is plotted in Fig. 4.10b. As shown in Fig. 4.10b, the optical signal shift at 1440 minutes 
does not tend to become saturated, indicating that some drugs are still not released.     
 







Fig. 4.10. (a) Measured interference optical signals at different release time; (b) Measured shift of the 
optical signal during the release procedure. 
 
    The drug release from the same FLEX-nanopore-TF device has been further monitored from 
first day up to 21 days. As shown in Fig. 4.11, it has been found the shift of the optical signal 
continues increase till 8 days, and the shift becomes smaller and eventually stops from 15 days, 
indicating the drugs have been totally released. It is anticipated the release time can further 
extended by increasing the size (diameter and depth) of the nanopores and the numbers of the 








Fig. 4.11. Measured drug release from the device: the shift of the optical signal stops after 15-day release, 
indicating the drug has been totally released. 
 
Summary 
A flexible nanopore thin film (FLEX-nanopore-TF) device for the controlled drug release and 
pressure sensing has been developed. The drug delivery device is realized by loading the drugs to 
the nanopore thin film and to the stacked nanoscale thin film using LbL nanoassembly process. It 
has been demonstrated up to 15 days drug release with the nanopore size of 50 nm and the LbL 
coating 10 layers of [PAA/GS/PAA/CHI] on the nanopore thin film. The release time can be 
further extended by increasing the nanopore size and density and the number of the 
[PAA/GS/PAA/CHI] layers. The pressure sensing is achieved due to the change of the incident 
angle of the illuminating light to the surface of the nanopore thin film when a pressure is applied 
on the FLEX-nanopore-TF device, resulting in the shift of the reflected optical signals from the 
device. It has been found its pressure sensitivity is ~0.01 nm/mmHg. The multiple functions 
offered by the FLEX-nanopore-TF make it an ideal wearable device for drug delivery and pressure 
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CHAPTER 5. HIGH-RESOLUTION, FLEXIBLE, AND TRANSPARENT NANOPORE 
THIN FILM SENSOR ENABLED BY CASCADED FABRY–PEROT EFFECT 
Chao Song, Xiaoke Ding, and Long Que. Optics Letters, vol. 43, no. 13, pp. 3057-3060, 2018.  
 
Abstract 
    This Letter reports a method to significantly improve the optical resolution of the anodic 
aluminum oxide (AAO) nanopore thin film sensor based on multi-cavity Fabry–Perot interference. 
The newly designed sensor is fabricated by bonding a layer of transparent polymer thin film (pTF), 
which is polydimethylsiloxane (PDMS), to a transparent AAO thin film to form a flexible pTF-
nanopore sensor. In comparison with the AAO nanopore thin film sensor, the pTF-nanopore sensor 
shows a much-improved quality (Q) factor and optical resolution. Typical thicknesses of a PDMS 
layer and an AAO layer of the pTF-nanopore sensor are 80 μm and 2 μm, respectively. The pTF-
nanopore sensor used for angle detection shows a sensitivity of 0.4 nm/deg with a resolution of 
0.2 deg. The pTF-nanopore sensor can also be used for temperature monitoring with a sensitivity 
of 0.2 nm/°C and a resolution of 1°C.  
Introduction 
    Anodic aluminum oxide (AAO) is one of the most prevalent nanomaterials used in biosensing, 
biomedical and energy storage applications [1-9]. AAO, a biocompatible and self-assembled 
nanostructure material, can be rapidly fabricated by an anodization process in a cost-effective 
manner. Taking advantages of the unique optical properties of arrayed nanopores, different types 
of sensors or devices  such as refractive index sensor  [1], gas sensor [2], colorimetric sensor [3], 
theophylline and plant hormone sensor [4-5], cancer biomarker sensor [6], solar energy device [7], 
fluorescence enhancement sensor  [8] and drug storage and release device [9,10]  have been 






(LOD) of biochemical such as disease biomarkers at a concentration in the picomolar or 
femtomolar range [6], further improvement of its LOD and optical resolution is still a very 
important topic. Some work has been done to optimize the LOD by tailoring the nanopore diameter, 
thickness and periodicity [11]. However, this method is complicated since it requires to tune the 
fabrication process parameters such as acid species and their concentrations, reaction temperature 
and the applied anodization voltage. Recently, it has been reported that the LOD of optical fiber-
based sensor can be improved by utilizing cascaded Fabry-Perot cavities  [12–18], which might be 
adopted to the AAO nanopore thin film based optical sensor to improve its LOD and resolution.  
 
Fig. 5.1. (a)  Sketches of an AAO nanopore thin film based optical sensor and its typical reflected 
interference signal, (b) sketches of the proposed pTF-nanopore sensor and its typical reflected interference 
signal. 
 
    In this letter, a method of improving the LOD of the AAO thin film based optical sensor is 
proposed by simply attaching a layer of transparent polymer thin film (pTF) to the AAO nanopore 
thin film. In this case, two Fabry-Perot cavities, the nanopore thin film and the pTF, are cascaded, 
resulting in a new type of optical sensor (pTF-nanopore sensor) as shown in Fig. 5.1b. The pTF 
layer is made from the transparent polymer polydimethylsiloxane (PDMS). The reflected optical 
signal (interference fringes) in Fig.1a from the AAO nanopore thin film alone has a Full-Width-
Half-Maximum (FWHM), typically in the range of 20-30 nm and its quality (Q) factor is ~20 at 






thickness (from 40 µm to 100 µm), the reflected optical signal (interference fringes) has small 
FWHM, typically in the range of 0.4-1.4 nm and its Q factor is 400-1,500. When pTF and AAO 
nanopore thin film is cascaded as a pTF-nanopore sensor, the reflected optical signal in Fig. 5.1b 
is the convolution of the optical signals from the AAO nanopore thin film and the optical signal 
from pTF, resulting in a significantly increased number of sub-interference fringes in the same free 
spectral range (e.g., sub-interference fringes from 0.56 µm to 0.61 µm in Fig. 5.1b), thereby 
improving optical resolution compared to AAO nanopore thin film-based sensor [18-21].   
Fabrication of pTF-nanopore Sensors 
The fabrication process flow is illustrated in Fig. 5.2a. Briefly, a cover glass is cleaned with acetone 
and isopropyl alcohol (IPA), followed by deposition of a thin layer of highly purified Al using E-
beam evaporation. Typical thickness of Al thin film is ~1.5 µm. After electrochemical reaction in 
0.3 M oxalic acid at 5.8 °C with a 30 V DC voltage using a two-step anodization process, Al thin 
film is transformed into AAO nanopore thin film [9]. Liquid PDMS is spin-coated on top surface 
of the AAO nanopore thin film, followed by being baked at 70°C for 2 hours. Then the PDMS thin 
film (pTF) along with the AAO thin film is gently peeled off from the glass substrate, resulting in 
a flexible transparent pTF-nanopore sensor. Photos of the fabricated sensors are shown in Fig. 5.2b 
and Fig. 5.2c.  The scanning electron microscope (SEM) image of AAO thin film is shown in Fig. 







Fig. 5.2. (a) Process flow for fabricating pTF-nanopore sensors, (b) a pen is wrapped by the flexible pTF-
nanopore sensor, (c) Text “OSA” can be clearly seen underneath the flexible transparent pTF-nanopore 
sensor, (d) SEM image of AAO nanopore thin film. 
 
Operational Principle of the pTF-nanopore Sensor 
    The experiment setup is schematically shown in Fig. 5.3a-b. A broadband white light source 
(Ocean Optics) is used as incident light. An optical fiber probe (Ocean Optics) is used to deliver 
the illuminating light to the pTF-nanopore sensor, and also collect the reflected signal from the 
sensor, which leads to a spectrometer (Ocean USB 4000) with a resolution of 0.22nm. As shown 
in Fig. 5.3c, the illumination light on a pTF-nanopore sensor will be reflected by three interfaces: 
Air/nanopore, nanopore/PDMS, PDMS/Air. The refractive index of each layer in the pTF-
nanopore sensor is summarized as the following:  air to be n1=1, AAO to be n2=1.67, PDMS to 
be n3=1.4 [18-19]. The thickness d2 of PDMS thin film is in the range of 40 µm-100 µm, and the 
thickness d3 of AAO nanopore thin film is ~2 µm.  The resolution of the pTF-nanopore sensor is 
determined by the quality (Q) factor, which is defined by [21]:  𝑄 = #
∆#
, where 𝜆 is the peak 
wavelength of the interference fringe and ∆𝜆 is its FWHM. The increased Q factor indicates the 
higher resolution of the pTF-nanopore sensor. Numerical simulation has been performed by 






distribution in Fig. 5.2d have been used directly to set up the model [22-23]. The thickness of pTF 
is set to be 50 µm, the AAO thickness is set to be 2 µm with average nanopore size of 30 nm. The 
interference pattern of 50 µm pTF alone, and the interference pattern of 2 µm AAO nanopore thin 
film alone are plotted in Fig. 5.3d. The interference pattern of a pTF-nanopore sensor is also plotted. 
As shown, the Q factor of the AAO nanopore thin film alone at 618 nm is ~20.5. The Q factor of 
the pTF-nanopore sensor at 618 nm becomes ~439.8, the same as that of pTF alone, which has 
been improved more than 20 folds, indicating the LOD of the pTF-nanopore sensors has been 
much improved in comparison with AAO nanopore thin film sensors. 
 
Fig. 5.3. (a) Experimental setup for the pTF-nanopore sensor, (b) close up of a pTF-nanopore sensor with 
incident light and the reflected light, (c) optical paths in the sensor, (d) the reflected interference patterns 
from a pTF with a thickness of 50 µm thin film, from a AAO nanopore thin film with a thickness of 2 µm, 
and from a pTF-nanopore sensor by cascading 50 µm pTF and 2 µm AAO nanopore thin film, respectively. 
The resolution of the spectrometer is assumed to be 0. 22 nm.  
 
Thick pTF Effect in a pTF-nanopore Sensor 
    As shown in Fig. 5.3, the thickness of the pTF in a pTF-nanopore sensor determines the Q factor 






a pTF-nanopore sensor, the resolution of the spectrometer should be at the same level of the sensor. 
Otherwise, the signal from the sensor cannot be resolved.  Note that the resolution of the 
spectrometer (Ocean USB 4000) is 0.22 nm in the spectrum from 350 nm to 1100 nm. In the 
following, the transducing signals from pTF-nanopore sensors with a large thickness (3000 µm as 
an example) of pTF layer is analyzed. 
    A pTF-nanopore sensor with pTF layer thickness of 3000 µm has been fabricated. The measured 
transducing signal by the spectrometer is shown in Fig. 5.4a. As shown, no interference pattern 
due to the pTF layer superposed on the interference pattern of AAO nanopore thin film is observed. 
Clearly the spectrometer cannot resolve the interference patterns contributed by the pTF layer, 
which is much smaller than its resolution (0.22 nm). In order to make the interference patterns 
visible, the resolution of the spectrometer needs to be lowered down.   
    To verify the assumption, a series of imaginary “spectrometers” with different resolutions is 
used to numerically analyze the interference patterns from the fabricated sensor, in which the pTF 
thickness is 3000 µm and the AAO thickness is 2 µm. Fig. 5.4b-d show the calculated results of 
the pTF-nanopore sensor, assuming the spectrometer has a resolution of 0.01 nm, 0.04 nm and 0.2 
nm in a spectral range from 590 nm to 630 nm (only from 590 nm to 594 nm shown for clarity), 
respectively. As shown in Fig. 4b, if the resolution is set to be 0.01 nm, even though there are 
massive interference peaks in the spectral range, they can be resolved. If the resolution is set to be 
0.04 nm, then each data point will be the average of every four adjacent data points from Fig. 5.4b, 
leading to Fig. 4c. It is clearly observed in Fig. 5.4c that the number of the interference peaks has 
been reduced significantly in the same spectral range with much lower contrast.  Furthermore, if 
the resolution is set to be 0.2 nm, each data point will be the average of every twenty adjacent data 






from 3000 µm pTF becomes very sparse and are almost gone, and even though the interference 
peak from AAO nanopore thin film is remained, very similar to the experimental results in Fig. 
5.4a measured by the spectrometer with a resolution of 0.22 nm. Hence, the resolution of the 
spectrometer should be considered as a limiting factor when a pTF-nanopore sensor is under design.  
 
Fig. 5.4. (a) Measured optical signal from a pTF-nanopore sensor with a thickness of the pTF of 3000 µm and a 
thickness of nanopore thin film of 2 µm by a spectrometer with a resolution of 0.22 nm, (b)-(d) the calculated 
spectrum when the resolution is set up to be 0.01 nm, 0.04 nm and 0.2 nm, respectively.  
 
 
Thin pTF Effect in a pTF-nanopore Sensor 
    The effect of the thicknesses of pTF in the range of 0 µm to 80 µm on the formation of sub-
interference fringes is also studied for a spectrometer with a resolution of 0.22 nm. The reflection 
spectrum from pTF-nanopore sensors with the pTF thickness ranging from 0 µm to 80 µm but with 
the same AAO nanopore thin film thickness of 2 µm is shown in Fig. 5.5a. The Q factor increases 
with the increased pTF thickness, indicating the resolution of the pTF-nanopore sensor can be 
improved by increasing pTF thickness. Given a spectrometer with a resolution of 0.22 nm, the 
FWHM can be as low as ~0.4 nm and Q factor can be as high as 1,544 at the wavelength of 618 
nm. Under this condition, the Q factor reaches 1,544 when the pTF thickness reaches 80 µm. And 






spectrum from pTF-nanopore sensors with the pTF thickness changing from 0 µm, 40 µm, 60 µm, 
and 80 µm has been experimentally examined, shown in Fig. 5.5b. It has been found that no sub-
interference fringes superposed on the interference pattern from AAO nanopore thin film when the 
pTF thickness is 0 µm. As the pTF thickness increases from 40 µm to 80 µm, there are 10, 16 and 
20 sub-interference fringes superposed on the interference pattern from AAO nanopore thin film 
in the wavelength range of 590 nm to 630 nm. As a result, the Q factor of the pTF-nanopore sensors 
increase. The studies of the thickness of pTF effect on the pTF-nanopore sensors provides a critical 
guideline to design this type of sensors if the resolution of the spectrometer is given.  
 
Fig. 5.5.  (a) The calculated spectrum of the pTF-nanopore sensors with the pTF of different thicknesses 
from 0 µm to 80 µm, the thickness of AAO nanopore thin film is fixed at 2 µm, (b) the measured spectrum 
of the pTF-nanopore sensors with the pTF of thicknesses from 0 µm to 80 µm using a spectrometer with a 




    The angle change can be monitored by the pTF-nanopore sensor. In the experiments, the sensor 
is positioned onto an optical rotation stage (Edmund Optics) which can change the angle with a 
step precision of 0.01 degree. Two types of sensors are tested. One sensor (SENSOR1) is the AAO 






sensor and the pTF thickness is 80 µm.  For both sensors, the thickness of AAO nanopore thin film 
is 2 µm. Simulation and experimental results for both sensors are shown in Fig. 5.6.  
 
Fig. 5.6. SENSOR1: (a) Calculated spectrum, (b) measured spectrum, and (c) calculated and measured peak 
shift of the fringes with the angle change. SENSOR 2: (d) Calculated spectrum, (e) measured spectrum, and 
(f) calculated and measured peak shift of the fringes with the angle change. 
 
    As shown in Fig. 5.6a-c for SENSOR1, no sub-interference fringes are superposed on one 
interference fringe (wavelength spans from 0.59 µm to 6.3 µm) from the AAO nanopore thin film.  
And no distinguishable peak shift is observed for every 0.2 degree angle change from 5 to 7 degrees. 
This indicates SENSOR1 is unsuitable for monitoring angle change. In contrast, for SENSOR2, 
there are 5 sub-interference fringes superposed on one interference fringe (wavelength spans from 
0.59 µm to 0.6 µm) from the AAO nanopore thin film. The shift of the peaks of interference fringes 
can be clearly observed when the angle is changed from 5 to 7 degrees as shown in Fig. 5.6d-f, 
resulting from the change of optical path difference from various interfaces (Fig. 5.3c). The angle 








    Two types of pTF-nanopore sensors have been fabricated to detection the temperature change. 
The thicknesses of nanopore thin film for both SENSOR3 and SENSOR4 are the same of 2 µm. 
The thicknesses of pTF in SENSOR3 and SENSOR4 are 1.4 mm and 80 µm, respectively. The 
sensors are placed onto a hotplate and temperature is increased from 25 °C degree to 30 °C with a 
step of 1 °C.  
 
Fig. 5.7. SENSOR3: (a) Calculated spectrum, (b) measured spectrum, and (c) calculated and measured peak 
shift of the fringes with the temperature change. SENSOR 4: (d) Calculated spectrum, (e) measured 
spectrum, and (f) calculated and measured peak shift of the fringes with the temperature change. 
 
 
    As shown in Fig. 5.7a-c for SENSOR3, no sub-interference fringes are superposed on one 
interference fringe (wavelength spans from 0.59 µm to 6.3 µm) from the AAO nanopore thin film. 
And no distinguishable peak shift is observed when the temperature changes from 25 °C to 30 °C. 
This indicates that SENSOR3 is unsuitable for monitoring temperature change. In contrast, for 






(wavelength spans from 0.59 µm to 0.62 µm) from the AAO nanopore thin film. The PDMS has 
a thermal optical coefficient of −4.5 × 10-./℃ [20], hence the temperature change leads to a 
change of refractive index of PDMS.  The shift of the peaks of interference fringes can be clearly 
observed when the temperature changes as shown in Fig. 5.7d-f, resulting from the change of 
optical path difference from various interfaces (Fig. 5.3c). The temperature sensitivity of 
SENSOR4 is 0.2 nm/℃.  
Summary 
    A new flexible and transparent pTF-nanopore sensor has been developed based on the multi-
cavity Fabry-Perot interference effect. Typical thicknesses of the pTF and nanopore layer in a pTF-
nanopore sensor are 80 µm and 2 µm, respectively. The pTF-nanopore sensor has been used for 
angle measurement and temperature sensing, offering significantly improved optical resolution in 
comparison with AAO nanopore thin film sensors. Given its high resolution, transparency and 
flexibility, this type of sensor can be potentially used as a wearable sensor to monitor disease 
biomarkers at a much lower concentration than that by using the AAO nanopore thin film sensors 
previously. In addition, this type of sensor can be potentially fabricated as a smart contact lens 
suitable for monitoring the intraocular pressure in real time, critical for glaucoma diagnosis and 
treatment.  
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CHAPTER 6. MULTIFUNCTIONAL SMART SOFT CONTACT LENS DEVICE 
ENABLED BY NANOPORE THIN FILM FOR GLAUCOMA DIAGNOSTICS AND IN 
SITU DRUG DELIVERY 
Chao Song, Gil Ben-Shlomo, and Long Que. Journal of Microelectromechanical Systems (published), 2019. 
Abstract 
In this section, we report a new power-free multifunctional soft contact lens device that can 
measure IOP, achieve extended drug delivery in situ, and detect glaucoma biomarkers, all within 
the same device. Experiments demonstrate that the contact lens sensor can detect Interleukin 12p70, 
one possible biomarker for glaucoma, in a concentration as low as 2 pg/ml in artificial tears. The 
sustained drug release of the contact lens device can last up to 30 days. In ex vivo tests using 
cadaver pig eyes, the sensor detected IOP in a range of 10 to 50 mmHg with excellent repeatability.  
Introduction 
    Glaucoma, a retinal neurodegenerative disease and a leading cause of blindness worldwide, is 
expected to affect about 112 million people by 2040 [1, 2]. Elevated intraocular pressure (IOP) is 
a primary contributing factor to glaucoma and its evaluation is used for diagnosis of the disease 
and monitoring the response to therapy. To date, patients’ IOP is monitored periodically at the 
ophthalmologist’s office, as tonometry requires specialized, expensive equipment and a trained 
professional to operate. Significant fluctuation in IOP and its increase above the normal range can 
be missed for months, until the next scheduled appointment, which can lead to substantial and 
irreversible retinal damage, loss of visual field, and even blindness. Hence, continuous or real-time 






the Triggerfish "smart" contact lens sensor for continuous monitoring of IOP has been introduced 
[3]. The IOP data is transmitted from the lens wirelessly to a small adhesive antenna placed on the 
face near the eye. The antenna then transmits the data to a portable recorder worn by the patient. 
However, the fabrication and operation of this and other reported IOP sensors are relatively 
complicated [4-9], and they require a power supply and some form of powered data transfer. 
Furthermore, they can measure IOP, but cannot deliver drugs in situ for the treatment of ocular 
diseases and/or detect their biomarkers in the tear film. 
    Application of topical anti-glaucoma medications is the first line of treatment for glaucoma and 
is crucial for prevention of retinal and optic nerve damage in glaucoma patients [10-12].  
Nonetheless, topical ocular drug delivery is challenging due to the physiological and anatomical 
constraints of the eye, and it is difficult to obtain the therapeutic drug concentration at the required 
site of action. As a result, only <1% of topically administered ocular drugs reaching the aqueous 
humor and ciliary body (the desired target tissue for anti-glaucoma drugs). This has led clinicians 
to recommend frequent dosing, which increases the risk for side effects and contributing to 
noncompliance by patients. Despite the grave consequences of noncompliance (i.e. visual 
impairment and blindness), it is a common phenomenon among glaucoma patients. To address this 
issue, recently, the conventional contact lens and the contact lens with integrated microtubes have 
been used for in situ drug delivery [13-16]. Anti-glaucoma drugs delivered by contact lenses lead 
to greater bioavailability of the drug, requiring lower concentration and quantity of the drug 
compared to eye drops. As a result, less side effects were noted in eyes treated by a drug-loaded 
contact lens compared to eye drops. However, the drug released from the contact lenses only lasted 
a short period of time (from a few hours up to four days). In addition, the drug release is not 






significantly subsides thereafter [17]. Ideally, a contact lens device should allow extended drug 
delivery with controlled release and greater bioavailability, thereby increasing efficacy, decreasing 
adverse effects and improving compliance.  
    Current glaucoma screening techniques, including IOP measurement, have poor sensitivity and 
are ineffective for early diagnosis of primary glaucoma (PG) [18, 19]. Given these limited 
screening methods, there is a great need for new biomarkers of early PG. Among many possible 
biomarkers [20, 21], of a particular interest is the role of cytokines, which are involved in oxidative 
stress and inflammation [20, 22]. However, in order to measure, screen, and validate the 
biomarkers, tears have to be obtained from patients and then analyzed using a high-sensitivity 
enzyme-linked immunosorbent assay (ELISA) [21, 23-24]. Current methods for tear-biomarker 
analysis are expensive and require the collection of tears from the patient. Given the limited 
amount of tears, the procedure of tear-sampling may be challenging and inconvenient to the patient. 
In recent studies, a graphene-silver nanowire (AgNW) field effect sensor fabricated on a contact 
lens was used to measure glucose levels in tears [25, 26]. Similarly, utilizing a contact lens device 
for the screening and measurement of biomarkers in tears could be a simple and efficient approach.  
    Herein, we report a novel, power-free, multifunctional smart contact lens that can accomplish 
three challenging missions: potentially real-time repeated IOP monitoring, in situ extended drug 
delivery, and detection of biomarkers of ocular diseases in tears, all with one single device. To the 
best of our knowledge, currently no reported technology can achieve these goals using a single 
device. The unique features of the multifunctional contact lens are summarized as follows: all three 
functional components of the contact lens (i.e. IOP sensing, extended drug delivery, and ocular 
disease biomarker detection) are fabricated from the same optically transparent and bio-compatible 






fabrication process and reducing its cost. Moreover, the IOP monitoring and detection of 
biomarkers for ocular diseases in the tear film are passive, and do not require a power source for 
their operation. Signals from these sensors are read by a portable spectrometer [28] or a 
smartphone-based spectrometer, and thus can be easily transmitted to the clinician, even from 
remote areas.     
Contact Lens Device Description 
    The sketch of the contact lens is shown in Fig. 6.1a.  There are three functions embedded in the 
silicone elastomer polydimethylsiloxane (PDMS)-based contact lens. The AAO thin film patterns 
can be arranged in the central region (CR) and surround the central region (SCR) of the contact 
lens. The AAO thin film patterns are used as IOP sensors, as sensors to detect the ocular-disease 
biomarkers, and used as drug containers for extended in situ drug delivery. Note that all three 
functions are enabled by the same AAO nanopore structures. Hence, the fabrication process of this 
device is significantly simpler and cheaper than other reported contact lens sensors.  The contact 
lens was designed so that there is a central region of about 4 mm in diameter in front of the pupil 
with no AAO thin film (Fig. 6.1a). However, it is noteworthy that due to the high transparency of 
the AAO thin film, it can also be positioned in front of the pupil without causing any visual deficit. 
The operational principles of the three functions are illustrated in Fig. 6.1b-d. For the biomarker 
detection (Fig. 6.1b), a biomarker-specific antigen is placed on the AAO surface. Once present in 
the tear-film, the biomarker binds to the antibody. As a result, the optical signal reflected from the 
AAO thin film shifts and can be evaluated by a spectrometer [30-32]. For in situ drug delivery 






eye, the drug releases to the tear film, then into the eye. For the IOP sensing (Fig. 6.1d), the AAO 




Fig. 6.1. (a) Schematic illustration of the smart contact lens: a layer of transparent bio-compatible nanopore 
thin film pattern integrated within the contact lens, used as pressure sensors for monitoring the intraocular 
pressure (IOP), for drug storage/delivery, and as biomarker detection sensors. (b) Close-up of the biomarker 
detection sensor: binding between the antibodies (Abs) and biomarker (antigens: Ags) causes the shift of 
the peaks of the optical signals. (c) Close-up of the drug storage and release: nanopores serve as nano-
containers to store the drug, and are covered by a thin layer of porous silicone that serves as a diffusion 
barrier for extended drug release. (d) Close-up of the IOP sensor: the peaks of reflected optical signal from 
contact lens device shift when the IOP changes. 
 
Material and Methods 
Chemicals and Materials 
    (1) For contact lens fabrication: PDMS and its cure agent were purchased from Dow Corning. 
The 3-D mold material for fabricating the AAO patterns is Methacrylic ester. (2) For biomarker 






98%), N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC), N-
Hydroxysuccinimide (NHS), ethanolamine (EA), Phosphoric acid (PPA) and PBS buffer were 
purchased from Sigma-Aldrich (Milwaukee, WI) and used without further purification. Deionized 
(DI) water was obtained from a DI water purification system (Millipore, FRANCE). TheraTears® 
Artificial tears (Akron; IL, USA)) were purchased from Walgreens. IL-12p was purchased from R 
& D Systems, Inc. (3) For drug release demonstration: fluorescein sodium salt (FSS) was 
purchased from Sigma, Inc. Timolol was purchased from SANDOZ, Inc. 
Optical Measurement for Biomarker 
    The detection setup of the nanopore-based sensors is the same as those previously reported [30]. 
Specifically, a broadband light source from a tungsten halogen lamp is coupled to a specifically-
designed optical fiber probe (Ocean Optics, Inc., Dunedin, FL, USA), which illuminates the sensor 
surface perpendicularly. The reflected signals (transducing signals) were collected by the same 
optical fiber probe, leading to an optical spectrometer (Ocean Optics, Inc.), which can detect 
optical spectrum from 350 nm to 1050 nm. 
Florescence Images and Analysis 
    Fluorescent images were taken using a fluorescence microscope equipped with a mercury arc 
lamp source (Olympus, Inc.), which has the following filter sets: FITC (excitation filter: 475-490 
nm; barrier filter: 500-540 nm); and TRITC (excitation filter: 545-565 nm; barrier filter: 580-620 
nm). For FSS, the FITC filter set was used for fluorescence measurement. The excitation optical 
spectrum was from 475 nm to 490 nm. A MatLab program has been written to read the files of 
fluorescence images, which are then converted to gray scale images from the color images. A 
horizontal cutline was obtained through the fluorescence image and the corresponding intensity 








Fabrication of Contact Lens and Characterization of Optical and Mechanical Properties 
    The fabrication process can be divided into two parts: contact lens fabrication and AAO sensor 
fabrication. For the contact lens fabrication, the fabrication process flow is illustrated in Fig. 6.2a. 
Briefly, PDMS is prepared with a volume ratio of 9:1 to curing agent with thorough mixing and 
degassing for 2 hours. A chrome steel ball is then positioned on a hotplate which has been 
preheated to 100 °C. Then, the liquid PDMS is poured onto the ball. Due to its high viscosity, 
liquid PDMS slowly flows down along the surface of the ball and is cured in 3 minutes. After 3 
minutes, a tube with a circular rim is firmly pressed against the ball to cut through the PDMS, and 
a contact lens with a circular boarder is obtained as shown in Fig. 6.2b. Using this fabrication 
process, the typical thickness of the contact lens is ~120 µm. 
    The fabrication process flow of the AAO sensors is illustrated in Fig. 6.2c-e. A covered glass 
slide is cleaned with Acetone, IPA and DI water, and dehydrated with nitrogen gas in sequence. 
Then, highly purified (99.99%) aluminum is deposited onto the cover glass slide with an E-beam 
evaporator. Al thin film is converted into AAO thin film by a two-step anodization process by 
immersing it in 0.3M oxalic acid at 5.8 °C for 3 hours [33]. Typical AAO thin film thickness is ~2 
µm. Liquid PDMS with volume ratio 15:1 to curing agent is then spin-coated onto the AAO thin 
film at a spinning rate of 3000 rpm for 30 seconds. The PDMS/AAO/glass substrate is then baked 
at 65 °C for 3 hours to complete the PDMS curing process. Typical PDMS thickness is ~30 µm. 
Then, PDMS/AAO thin film is gently peeled off the glass substrate. Due to the barrier layer 
underneath the AAO thin film [34], the nanopores on the peeled PDMS/AAO thin film are not 






In order to remove the barrier layer, AAO etchant is applied on the AAO thin film for 30 min, 
followed by a rigorous rinse by flowing DI water. This way, the nanopores in the AAO thin film 
are totally opened. A mold fabricated by 3D printing (Fig. 2d) is utilized to cut the PDMS/AAO 
thin film into desired patterns (Fig. 6.2e). Then the patterned PDMS/AAO thin film is bonded to 
the PDMS contact lens to form the new contact lens device as shown in Fig. 6.2f-g. Photos of a 
fabricated PDMS contact lens device is shown in Fig. 6.2h-i. A SEM image showing the nanopore 
in the AAO thin film is given in Fig. 6.2j. 
 
 
Fig. 6.2.  (a-b) Process flow to fabricate the contact lens; (c-e) process flow to fabricate the patterned AAO 
nanopore thin film sensors; (f-g) sketch of the smart contact lens device; (h) photo of a fabricated smart 
contact lens device. In this design, the AAO thin film in the pupil region of the contact lens are made highly 
transparent compared to AAO thin film around the pupil region; (i) photo of a fabricated smart contact lens 
device. In this design, there is no AAO thin film in the pupil region; (j) SEM images of the AAO thin film 
of the sensors on contact lens; (k) Measured transmittance for contact lens device and other materials; (l) 






    The optical transparency of the fabricated contact lens is evaluated. As shown in Fig. 6.2k, the 
transmittance of the AAO/PDMS contact lens is ~92%. For comparison, the transmittance for eye 
glasses is ~85% and for PDMS is ~95%. These measurements indicate that the highly transparent 
AAO thin film is a suitable material to be integrated with the PDMS-based contact lens device 
with negligible effect on transparency. Nonetheless, a clear area of 4 mm in diameter at the central 
visual axis (i.e. in front of the pupil) is left without AAO thin film to allow even greater 
transparency. The effect of the mechanical deformation of the contact lens on its transmittance has 
also been evaluated. The measured transmittance under 1000-cycle bending and stretching is 
shown in Fig. 6.2l. After 1000-cycle bending and stretching, it has been found that the 
transmittance shows negligible changes and no cracks can be found in the AAO thin film, 
indicating its high mechanical flexibility and optical transparency suitable for an IOP sensor.     
 
Fig. 6.3.  (a) Schematic illustration of the chemical functionalization steps of the sensor surface for detecting 
biomarker IL20p70; (b) representative measured optical signals showing the optical signal shift after 
artificial tear and 1pg/ml IL 12p70 in artificial tear is applied on the contact lens sensor, respectively; (c) 







In Vitro Detection of Biomarker in Artificial Tears by Means of the Novel Contact Lens 
    Biomarker detection in the tear film can assist the diagnosis of early glaucoma, which can 
potentially provide a complementary diagnosing method to the widely used IOP measurement 
method. To date, there are no known highly reliable liquid biomarkers for glaucoma diagnosis, 
even though many potential promising ones have been identified [20, 22-24]. One possible 
biomarker is cytokine Interleukin 12 (IL-12p70), since  recent studies have found that the mean 
concentrations of IL-12p70 in tear film were significantly lower for the diagnosed primary open-
angle glaucoma (POAG) group compared to the control group (3.94 ± 2.19 pg/mL in control vs 
2.31 ±1.156 pg/mL in POAG; P=0.035) [21]. This indicates that measuring the concentration of 
IL12p70 in the tear film could aid with the early diagnosis of glaucoma, in addition to IOP 
measurement. As aforementioned, quite a few promising biomarkers have been reported; ideally, 
all of them can be screened and validated in the tear film for accurate diagnosis. In this technical 
demonstration, we have only detected IL-12p70 by the nanopore thin film sensor embedded in the 
contact lens as an example. The same principle can be applied for other biomarkers by 
functionalizing different types of antibodies or aptamers on the sensor surface. 
    The biomarker is monitored by measuring the optical reflection signal from the nanopore thin 
film sensor embedded in the contact lens, similar to our previous work [30], before and after the 
biomarker is applied to the sensor. The binding of the biomarker with the functionalized surface 
of the sensor results in a change of the optical path difference (OPD). The higher the concentration 
of the biomarker, the larger the shift of the optical signal.  
    To this end, the surface of the sensor needs to be functionalized with human IL-12p70 antibody 
first. The detailed procedure is illustrated in Fig. 6.3a. The contact lens sensor surface coated with 






dimethylaminopropyl) carbodiimide (EDC)/N-hydroxysulfosuccinimide (NHS) chemistry. 
Briefly, the sensor surface is immersed in the 10 mM HSC10COOH/HSC8OH overnight at 4 °C 
and then washed with pure ethanol and Millipore DI water. After the surface is dried, it is immersed 
in a mixed solution of NHS and EDC (NHS 0.2 M, EDC 0.05 M) for 2 hours. The sensor surface 
is then washed with DI water and immersed in the 5 µM IL-12p70 antibody solution overnight. 
This is followed by applying 100μL 1 M ethanolamine (EA) to block the unoccupied 
HSC10COOH/HSC8OH sites activated by the EDC/NHS. Finally, the sensor surface is rinsed 
with the PBS buffer to remove non-specifically adsorbed proteins. At this stage, the sensor is ready 
for measuring the biomarker IL-12p70.  
    Mouse IL-12p70 diluted in artificial tears (TheraTears, Akron) with a concentration ranging 
from 0 pg/ml to 10 pg/ml was applied onto the sensor surface for 2 hours incubation in sequence, 
and the shifts of the reflected light were collected. As shown in Fig. 6.3b-c, by increasing the 
concentration of IL-12p70 from 0 pg/ml to 10 pg/ml, the shift increases from 1.2 nm to 9 nm. This 
indicates that the sensitivity of the contact lens sensor is ~0.78 nm/(pg/ml) for IL-12p70 detection. 
Note that the shift of the artificial tears (0 pg/ml of IL-12p70) is 1.2 nm, indicating the possible 
non-specific binding of the minerals in the artificial tears with the antibodies of IL-12p70, which 
can be nulled by subtracting the shift due to the artificial tear. 
Drug Release 
    In previous studies, loading a drug to a contact lens was achieved by immersing a commercially 
available contact lens in a drug solution; hence, impregnating the lens with the drug. Drug release 
from the drug-impregnated lens was achieved by simple passive diffusion. Thus, drug release 
lasted for only a short period of time, from a few hours up to four days. In order to achieve an 






the therapeutic range), the nanopores in the AAO thin film have been used to store the drugs, 
thereby enabling a sustained drug release and therapeutic effect. In this demonstration, Timolol, a 
widely used anti-glaucoma drug [15], was mixed with a fluorescein dye (fluorescein sodium saline: 
FSS) solution, and then loaded into the nanopores of the AAO thin film (Fig. 6.4a). The surface of 
the AAO thin film is hydrophilic due to a brief oxygen plasma treatment, which facilitates the load 
of the drug/FSS into the nanopores.  Specifically, 500 µl FSS is diluted into 10 µg/ml and then 
mixed with Timolol, then the solution is applied onto the AAO thin film, allowing to air-dry under 
normal room conditions. After the surface is dried, the contact lens is immersed into artificial tear 
to mimic the aqueous environment of the ocular surface (i.e. tear film). Under this condition, the 
release of the drug/FSS is mainly by passive diffusion of the drug/FSS to the artificial tear [14]. 
As the drug/FSS is being released from the AAO thin film, the fluorescence intensity of the AAO 
thin film is decreased. At pre-determined time points (see below), the contact lens was removed 
from the artificial tear bath and imaged by a fluorescence microscope (Olympus, Inc.). 
 
Fig. 6.4.  (a) Sketch: drugs (timolol + FSS as drug model) loaded to the contact lens device and its close-
up; (b) fluorescence images at different release time points; (c) fluorescence intensity and corresponding 







    A series of representative fluorescence images for different time points are shown in Fig. 6.4b. 
As shown in these images, the fluorescence intensity of the AAO thin film decreases gradually 
after being immersed into artificial tear for 6 hrs, 2 days, 5 days, 14 days, and 30 days, respectively, 
corresponding to the drug/FSS release into the artificial tear. The corresponding average 
fluorescence intensity was obtained by using the imaging analysis toolbox in Matlab, which is 
shown in Fig. 6.4c. As shown, after 30 days, the fluorescence intensity decreased ~25%. In order 
to quantify the drug release over time, calibration experiments have been performed. In the 
calibration experiments, 10ug/ml, 5ug/ml, 1ug/ml, 0.5ug/ml, 0.1ug/ml FSS solution was applied 
onto the AAO thin film and fluorescence images were taken after the contact lens surface was 
allowed to air-dry under normal room conditions. The fluorescence intensity and its corresponding 
concentration range of FSS were then plotted to calculate the drug release over time (Fig. 6.4c). 
Our results show that ~90% of the drug was released after 30 days. It is anticipated that if the drug 
has been totally released, the fluorescence intensity should be close to zero, given small 
fluorescence emission from AAO and PDMS [36]. These experiments prove that extended drug 
release from a contact lens device can be achieved by using nanopores as part of a contact lens 
device as a drug depot that allows long term drug release. 
Ex Vivo Monitoring of Intraocular Pressure (IOP) 
    As demonstrated previously, the flexible AAO nanopore thin film can be used as a pressure 
sensor [28]. It is well known that increased IOP is a major risk factor for, and one of the clinical 
signs of, glaucoma. Frequent measurement of IOP is therefore critical for diagnosing glaucoma 
and monitoring response to therapy. Herein, the ex vivo evaluation of IOP using a contact lens 
with AAO nanopore thin film is demonstrated. Changes in IOP lead to changes of corneal 






in a change to the contact lens curvature as well. This change in contact lens curvature will lead to 
a change in optical reflection, or a shift of signal, from the contact lens. Specifically, the light 
reflection angles from the contact lens is changed. Different reflection angles result in different 
optical paths and different interference spectrums. The IOP can be calculated as a function of 
spectrum shift (Fig. 6.5). In this part of the experiment, the reflection spectrum was measured from 
SCR sensors on the contact lens. 
 
 
Fig. 6.5.  (a) The change of corneal curvature due to IOP consequently leads to curvature change of the 
contact lens; as a result, the reflected optical signal from the contact lens changes; (b) Measurement setup: 
a contact lens is placed onto a cadaver pig’s cornea, and signal shift us measured by means of an optical 







Manometry on a cadaver pig eye was used, as previously described [37], to evaluate the optical 
signal shift from the contact lens in response to IOP changes (Fig. 6.5b). Briefly, the cadaver eye 
was secured on a ring of clay at the same height as a digital manometer.  The anterior chamber of 
the eye was cannulated at the limbus, at the 3 and 9 o’clock positions, using a 27-gauge needle. 
One needle was connected to a digital manometer and the other was connected to a 1 L 0.9% NaCl 
reservoir bag. Leakage around the needles was not observed following channelization of the 
anterior chamber. The IOP, controlled by adjusting the height of the reservoir bag, was increased 
from 10 to 50 mmHg at 10 mmHg intervals. The fabricated contact lens was applied onto the 
cornea and was repeatedly lubricated with physiological saline solution throughout the experiment.  
An optical fiber probe (Ocean Optics, Inc.) connected to a spectrometer (Ocean Optics, Inc.) 
was then set up perpendicular to the contact lens to deliver illumination and collect light reflection 
(Fig. 6.5b). The spectrometer was connected to a computer which displayed and recorded the 
reflection spectrum. The results are shown in Fig. 6.5c: by increasing the IOP from 10 mmHg to 
50 mmHg, the peaks of the reflection spectrum shifted by 0.8 nm to a longer wavelength. By 
decreasing the IOP from 50 mmHg to 10 mmHg, the peaks of the reflection spectrum shifted by 
0.8 nm to a shorter wavelength. For both cases, measurements showed excellent repeatability for 
the spectrum shift. The contact lens IOP sensor has a sensitivity of 0.02 nm/mmHg (Fig. 6.5d), 








Fig. 6.6.  (a) Sketch showing light path to the IOP sensor at the CR for the measurement; (b) sketch showing 
light path to the SCR IOP sensor for the measurement; (c) Measured optical signal from SCR IOP sensor 
on the contact lens; (d) Measured optical signal from the CR IOP sensor; (e) Measured shift of the optical 
signal under different IOPs for CR and SCR sensors; (f-h) the simulated results for CR and SCR IOP sensors 
under different IOPs (equivalent to different incident angle of incident light). 
 
IOP Sensors at the Central Region and Surrounding the Central Region on Contact Lens 
    In this section, the spectrum shift as a function of IOP was evaluated by CR and SCR sensors. 
The experimental design was similar to that described above and in Fig. 6.5. However, in this 
experiment, the reflected light was measured from sensors at the CR and SCR as illustrated in Fig. 
6.6a-b. The results are presented in Fig. 6c-e. Our results indicate that the optical signals from the 
CR sensors show a very small shift as a response to IOP change, while a much larger shift was 






sensor as demonstrated in our lab previously [28]. Hence, in the simulation, the responses of the 
contact lens were modeled by changing the incident angle of the light as shown in Fig. 6.6f-h, 
which matches the experimental results where the angle changes from 0° to 0.8°. These results 
suggest that the IOP sensors in the CR are less sensitive to the IOP changes than the SCR sensors. 
This is due to the fact that the IOP sensors in the CR have a much smaller curvature than that of 
the IOP sensors in the SCR. As a result, the incoming light to the SCR sensors has a larger incident 
angle than that of the sensors in the CR. In addition, the curvature in the CR changes much less 
than that of the SCR with the same change in IOP. Hence, the CR sensors are much less sensitive 
to IOP changes (i.e., smaller optical signal shift) than the SCR sensors. 
Discussions and Conclusion 
    The three functions of the smart contact lens have been demonstrated herein. It has been found 
that (1) one of the possible glaucoma biomarkers (IL-12p70) can be detected in artificial tears 
successfully; (2) the sustained drug release can last at least 30 days, and (3) the IOP can be 
monitored with excellent repeatability. Overall, the new smart contact lens device with the three 
functions opens the possibility for quantitative analysis of the protein biomarkers in tears, the 
repeated real-time IOP monitoring, and the extended in situ drug delivery.  
    For future in vivo biomarker evaluation in the tear for both healthy people and glaucoma patients, 
the procedure is summarized as follows. After the sensors on contact lens are functionalized with 
a specific antibody [24], it will be worn by a healthy people or a patient for one hour. Then, it will 
be removed from the eye and rinsed rigorously with buffer solution before taking the 
measurements. With different antibodies, the concentration profile of the proteins in tear film can 
be obtained as a function of time. This way, the possible biomarkers for glaucoma or other ocular 






combination of drugs can be loaded to the contact lens to examine their clinical efficacy. It should 
be noted that the release of drugs loaded into the contact lens can be further triggered by the IOP 
in glaucoma patients. In other words, the release rate of the drug is only dependent on the diffusion 
process if IOP remains within the normal range. However, the release rate will increase when the 
IOP increases since the contact lens will be stretched; as a result, the release rate from the 
nanopores will be increased. Similarly, the drug release rate will decrease when the IOP decreases. 
This drug release mechanism is similar to a strain-triggered drug release reported before [38], 
which means that the drug release rate of the contact lens device can be self-regulated based on 
the IOP, increasing the drug release (hence the dose) when the IOP spikes. Furthermore, we have 
concluded that the SCR IOP sensors should be used for IOP monitoring (rather than the CR 
sensors), as they are more sensitive to IOP changes.  
    It should be noted that while the IOP can cause the changes of the corneal curvature, other 
factors (eyeball swelling, eyeball temperature change, etc.) can also cause the same changes. 
Hence, the diagnosis of glaucoma cannot be very accurate by measuring IOP only. As 
demonstrated, the reported contact lens device can also measure the glaucoma biomarkers in tears. 
It is anticipated that by combining the IOP measurements and the glaucoma biomarker 
measurements, more accurate diagnosis of glaucoma can be achieved. In addition, for future in 
vivo IOP measurements or possible clinic use of this reported contact lens device, an optical reader 
and the related accessories also need to be developed. 
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CHAPTER 7. GENERAL CONCLUSIONS AND FUTURE WORK 
With all current work be done, two AD biomarkers have been successfully detected with label-
free AAO biosensors. Contact lens targeting glaucoma diagnosis and treatment has also been 
fabricated and verified in prospective of proof of principle. To push such sensors to real life 
application, there is still way to go.  
For the diagnosis of AD, the ultimate goal of AAO based microfluidics device will be to realize 
the point-of-care (POC) diagnostics. Toward this goal, several aspects need further studies and 
development in the future. The very first thing would be, when performing biomarker detection, 
plasma sample would be used instead of cerebrospinal fluids samples. This is mainly due to the 
much easier access of plasma sample rather than cerebrospinal fluid samples. However, 
biomarkers like Aβ42 and Ttau shows much lower concentration in plasma compared to 
cerebrospinal fluid. This would pose new challenge onto microfluidics devices in terms of 
sensitivity and detection of limit. Furthermore, there are other reported biomarkers related to AD 
such as pTau, which could result in tangles of helical and straight filaments, leading to similar 
consequences of Aβ42 deposition onto brain tissues.  
For the development of contact lens device for glaucoma diagnosis and treatment, the first step 
work of multifunctional contact lens will be in vivo drug release test of this contact lens on animals, 
especially on dogs. This step is crucial because of its importance for potential realistic applications. 
The contact lens drug delivery method would replace tear drop drug delivery method in such 
experiments to perform longitudinal observation of treatment. Another improvement could be 
made to contact lens is the pressure sensing method change. In future design, several MEMS 






microstructures, pressure sensing could be realized. All these improvements can make the contact 
lens device more promising for future point-of-care (POC) measurement.  
A mutual future work of AD and contact lens project is the development of smartphone based 
miniaturized measurement system. Such system can be used at home or the source-limited settings 
by the patients themselves with help from family members if needed, and is very critical for 
realizing point-of-care (POC) diagnostics. In addition, with such system, regularly repeated 
monitoring of AD and glaucoma under drug treatment can be realized.  
  
